Document:

License Agreement

 Exhibit 10.1 
  
 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as **. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  
 LICENSE AGREEMENT 
  
 dated as of April 7th,
2004 
  
 by and between 
  
 Unigene Laboratories, Inc. 
  
 and 
  
 Novartis Pharma AG 

 
TABLE OF CONTENTS 
  

					
		
	ARTICLE I DEFINITIONS	  	1
		
	ARTICLE II LICENSE GRANTS	  	6
			
	 2.1.
	  	License Grant from Unigene to Novartis	  	6
			
	 2.2.
	  	Reservation of Rights to the Licensed Technology	  	6
			
	 2.3.
	  	Novartis Sublicensing Rights	  	7
			
	 2.4.
	  	Improvement License Grants from Novartis to Unigene to manufacture API	  	8
			
	 2.5.
	  	Improvement License Grants from Novartis to Unigene to manufacture proteins or peptides other than API	  	9
			
	 2.6.
	  	Licensed Technology Facilities	  	9
		
	ARTICLE III PAYMENTS	  	9
			
	 3.1.
	  	Initial Fee to Unigene	  	9
			
	 3.2.
	  	Milestone Payments to Unigene	  	9
			
	 3.3.
	  	Unigene Licensed Technology Royalties	  	11
		
	ARTICLE IV TECHNOLOGY TRANSFER	  	13
			
	 4.1.
	  	Unigene Know-How and Material Transfer	  	13
			
	 4.2.
	  	Assistance	  	13
			
	 4.3.
	  	Technical Support beyond the Technology Transfer Plan	  	13
			
	 4.4.
	  	Cost of Technology Transfer	  	14
		
	ARTICLE V SUPPLY AND MANUFACTURE	  	14
			
	 5.1.
	  	Unigene Supply to Novartis	  	14
			
	 5.2.
	  	Novartis Supply to Unigene	  	14

  

 - i - 

					
		
	ARTICLE VI INTELLECTUAL PROPERTY	  	15
			
	 6.1.
	  	Ownership and Inventorship of Sole and Joint Improvements	  	15
			
	 6.2.
	  	Filing, Prosecution, Maintenance and Enforcement of Patents	  	15
		
	ARTICLE VII REPRESENTATIONS, WARRANTIES AND COVENANTS	  	19
			
	 7.1.
	  	Warranties	  	19
		
	ARTICLE VIII CONFIDENTIALITY AND EXCHANGE OF INFORMATION	  	20
			
	 8.1.
	  	Confidential Information	  	20
			
	 8.2.
	  	Permitted Disclosures	  	21
			
	 8.3.
	  	Public Announcements	  	22
			
	 8.4.
	  	Publications	  	22
			
	 8.5.
	  	Bankruptcy	  	23
		
	ARTICLE IX INDEMNIFICATION	  	23
			
	 9.1.
	  	Indemnification of Novartis	  	23
			
	 9.2.
	  	Indemnification of Unigene	  	23
			
	 9.3.
	  	Procedure	  	24
		
	ARTICLE X DISCLAIMER OF WARRANTIES	  	24
		
	ARTICLE XI TERM AND TERMINATION	  	25
			
	 11.1.
	  	Term	  	25
			
	 11.2.
	  	Termination for Material Breach	  	25
			
	 11.3.
	  	Termination for Insolvency; Retention of License	  	25
			
	 11.4.
	  	General Effect of Termination	  	26
		
	ARTICLE XII MISCELLANEOUS	  	27

  

 - ii - 

					
			
	 12.1.
	  	Governing Law	  	27
			
	 12.2.
	  	Waiver	  	28
			
	 12.3.
	  	Assignment	  	28
			
	 12.4.
	  	Notices	  	28
			
	 12.5.
	  	Force Majeure	  	29
			
	 12.6.
	  	Independent Contractors	  	29
			
	 12.7.
	  	Other Obligations	  	29
			
	 12.8.
	  	Severability	  	30
			
	 12.9.
	  	Further Assurances	  	30
			
	 12.10.
	  	Entire Agreement, Waivers, Etc.	  	30
			
	 12.11.
	  	Headings, Construction and Interpretations	  	30
			
	 12.12.
	  	Counterparts	  	31

  

 - iii - 

 This License Agreement (this “Agreement”), dated as of April 7th, 2004 (the “Effective Date”), is made between Novartis Pharma AG, a Swiss corporation (“Novartis”) and Unigene Laboratories, Inc., a
Delaware corporation (“Unigene”) (each a “Party” and collectively, the “Parties”). 
  
 R E C I T A L S 
  
 WHEREAS, Unigene has developed certain proprietary technology related to the manufacture of API, Intermediate and Amidating Enzyme; 
  
 WHEREAS, Unigene is the owner of all right, title and interest in, or otherwise controls, certain Unigene Patent Rights and Unigene Know-How which relate to the
manufacture of API, Intermediate and Amidating Enzyme; 
  
 WHEREAS, Unigene
desires to grant to Novartis and Novartis desires to obtain, an exclusive, worldwide license under this Agreement for Novartis and/or its Affiliates to develop, have developed, manufacture, use, import and export API, Intermediates and Amidating
Enzyme for use in Novartis and Unigene Drug Products; 
  
 WHEREAS, Unigene
desires to supply, and Novartis desires to be supplied with API suitable for a ** Clinical Study for the development of Novartis’ Oral Product according to the terms of the Clinical Supply Agreement attached hereto as Exhibit A; 
  
 WHEREAS, the parties shall negotiate in good faith the terms and conditions of a
clinical and a commercial supply agreement to cover the supply of API for clinical and commercial use in Unigene’s Drug Products (“Product Supply Agreement” and the “Contract Manufacturing Agreement) as set forth below.

  
 NOW, THEREFORE, in consideration of the mutual covenants set forth in
this Agreement, Novartis and Unigene, intending to be legally bound, hereby agree as follows: 
  
 ARTICLE I 
 DEFINITIONS 
  
 1.1. “Affiliate” means any legal entity (such as a corporation, partnership, or limited liability company)
that Controls, is Controlled by or is under common Control with a Party to this Agreement. For the purposes of this definition, the term “Control” means: (i) beneficial ownership of at least fifty percent (50%) of the voting securities of
a corporation or other business organization with voting securities (or such lesser percentage which is the maximum allowed by a foreign corporation in a particular jurisdiction); (ii) a fifty percent (50%) or greater interest in the net assets or
profits of a partnership or other business organization without voting securities; or (iii) the ability to direct the affairs of any such entity. 
  
 1.2. “Amidating Enzyme” means a recombinant enzyme used to convert non amidated peptides or proteins to amidated peptides or proteins.

  

 - 1 - 

 “API” or “Active Pharmaceutical Ingredient” means recombinant salmon
calcitonin manufactured under or using the Licensed Technology in bulk active ingredient form. 
  
 “Calendar Quarter” means a period of three (3) consecutive calendar months ending on March 31, June 30, September 30 or December 31. 
  
 “Calendar Year” means a period of twelve (12) consecutive calendar months beginning on January 1 and ending
on December 31. 
  
 “Clinical Supply Agreement”
means that certain clinical supply agreement, dated as of the date hereof, by and between Novartis and Unigene, which is attached hereto as Exhibit A. 
  
 “Commencement of **” means the date **. 
  
 “Commencement of **” means the date **. 
  
 “Competing Product” means any product sold by a Third Party that contains API. Affiliates, sublicensees, Joint Ventures and distributors
of Unigene shall not be considered to be Third Parties. 
  
 “Confidentiality Agreement” means the Confidentiality and Non-Disclosure Agreement, dated November 6, 2002, between Novartis AG and Unigene. 
  
 “Confidential Information” means (i) any proprietary or confidential information or material in tangible
form disclosed hereunder that is marked as “Confidential” at the time it is delivered to the receiving Party, (ii) proprietary or confidential information disclosed orally hereunder which is identified as confidential or proprietary when
disclosed and such disclosure of confidential information is confirmed in writing within forty-five (45) days thereafter by the disclosing Party. 
  
 “Contract Manufacturing Agreement” shall have the meaning assigned to it in Section 5.2.1 
  
 “Control,” “Controls,”
“Controlled,” or “Controlling” means (except with respect to “Affiliate” as defined in Section 1.1) possession of the ability to grant the licenses or sublicenses as provided herein without violating the
terms of any license agreement or other arrangement with any Third Party, or any government regulation or statute. 
  
 “Effective Date” means the date set forth above. 
  

“Field” means the use by oral administration of the API for the prophylactic and/or therapeutic treatment of any human diseases or
disorders, including, but not limited to, osteoporosis. 
  

 - 2 - 

 “FDA” means, with respect to the United States, the United States Food and Drug
Administration, any successor entity thereto, or any equivalent foreign regulatory authority(ies) in a particular country of the Territory. 
  
 “First Commercial Sale” means the first sale of any Novartis Drug Product to a Third Party by Novartis or its respective Affiliates or
permitted sublicensees. 
  
 “Future Novartis
Products” means any and all drug products developed or licensed by Novartis for use outside the Field during the term of this Agreement, but not yet developed or licenced upon Effective Date, in any formulation containing or incorporating
API, alone or in combination with any pharmacologically active ingredient. 
  
 “Improvements” shall collectively mean Joint Improvements, Novartis Non-Severable Sole Improvements, Novartis Severable Sole Improvements and Unigene Sole Improvements, and Non-Severable Joint
Improvements. 
  
 “Intermediate” means API
precursors generated during the process of manufacturing API. 
  
 “Joint Improvements” means any improvements, inventions, discoveries, processes, improved cell lines, cell banks, clones, vectors, cassettes, and other knowledge, whether or not patentable (including patents, patent
applications, divisions, continuations, continuation-in-part, reissues, reexaminations, extensions or supplemental patent certificates) that are (a) jointly made after the Effective Date of this Agreement by at least one individual or individuals
under an obligation to assign their rights to such improvements to Unigene and/or its Affiliate as applicable and at least one individual or individuals under an obligation to assign their rights to such improvements to Novartis and/or its Affiliate
as applicable and (b) implemented in ** and c) not derived from ** or from ** or otherwise by Unigene and/or its Affiliate as applicable, and d) not derived from ** or from ** or otherwise by Novartis and/or its Affiliate as applicable. 

 
 “Joint Venture” means any entity, collaboration or
association between Unigene and a Third Party for, inter alia, manufacturing API solely for use in Other Unigene Products, in which Unigene has a ** or greater direct ownership of the interest of such entity, collaboration or association and has a
significant and active management role. 
  
 “Licensed
Technology” means the **. 
  
 “Net
Sales” means with respect to the Novartis Drug Products, the gross amount invoiced by Novartis, its Affiliates, its sublicensees, its co-promoters, its co-marketers or a joint venture to which Novartis, its Affiliates or sublicensees are a
party, 

  

 - 3 - 

 
to unrelated Third Parties on sales of Novartis Drug Product in the Territory less the following customary and reasonable deductions for the Novartis Drug
Products: 
  
 Trade, quantity and cash discounts allowed; 
 ** 
  
 Actual Novartis Drug Product returns and allowances; 
 ** 
 ** 
  
 “Non-Severable Joint
Improvements” means all improvements, inventions, discoveries, processes, improved cell lines, cell banks, clones, vectors, and cassettes, and other knowledge, whether or not patentable (including patents, patent applications, divisions,
continuations, continuation-in-part, reissues, reexaminations, extensions or supplemental patent certificates) that are (a) derived from **, or from ** as applicable, and implemented in the ** and (b) made after the **, provided, however, that if
such improvement was **, as applicable, ** shall be deemed to be a **. ** shall be deemed to be a **. 
  
 “Novartis Non-Severable Sole Improvements” means all improvements, inventions, discoveries, processes, improved cell lines, cell banks,
clones, vectors and cassettes, and other knowledge, whether or not patentable (including patents, patent applications, divisions, continuations, continuation-in-part, reissues, reexaminations, extensions or supplemental patent certificates) that are
(a) derived from ** and (b) made after the ** as applicable. 
  
 “Novartis’ Oral Product” means the drug product for use in the Field in development by Novartis upon the Effective Date, in finished pharmaceutical form suitable for oral administration, containing or incorporating
API, alone or in combination with any pharmacologically active ingredient. 
  
 “Novartis Drug Products” means (a) the Novartis Oral Product, (b) the Future Novartis Products and (c) the Other Novartis Products. 
  
 “Novartis Severable Sole Improvements” means all improvements, inventions, discoveries, processes, improved
cell lines, cell banks, clones, vectors, cassettes, and other knowledge, whether or not patentable (including patents, patent applications, divisions, continuations, continuation-in-part, reissues, reexaminations, extensions or supplemental patent
certificates) that are either (a) derived from ** upon having been made after the ** or (b) derived by any individual or individuals **. 
  
 “Other Novartis Products” shall mean any and all drug products developed or licensed by Novartis for use outside the Field upon the
Effective Date, in any formulation containing or incorporating API, alone or in combination with any pharmacologically active ingredient. 
  

 - 4 - 

 “Other Unigene Products” shall mean any and all drug products developed or licensed by
Unigene for use outside the Field upon the Effective Date and/or during the term of this Agreement, in any formulation (in particular but not limited to nasal and/or injectable), containing or incorporating API, alone or in combination with any
pharmacologically active ingredient. 
  
 “** Clinical
Studies” means the ** clinical study **. 
  
 “**
Clinical Studies” means ** clinical trials **, as prescribed by applicable FDA regulations. 
  
 “Process Transfer Information” means the information to be supplied by Unigene as set forth in Section 4.1. 
  
 “Term” means the term of this Agreement as set forth in
Section 11.1. 
  
 “Territory” means all the
countries and territories of the world. 
  
 “Third
Party(ies)” means any party(ies) other than Unigene, Novartis or their respective Affiliates. 
  
 “Unigene’s Oral Product” means the drug product in development by Unigene upon Effective Date for use in the Field, containing or
incorporating API, alone or in combination with any pharmacologically active ingredient. 
  
 “Unigene Drug Product” means (a) the Unigene Oral Product and (b) the Other Unigene Products. 
  
 “Unigene Know How” means all **, ideas, inventions, data, instructions, processes **, formulas, expert opinions and information,
including, without limitation, biological, chemical, pharmacological, physical and analytical, clinical, safety, manufacturing and quality control data and information, in each case, which are necessary or useful for the development, testing, use,
manufacture or sale of ** and which is in the possession of and owned or Controlled by Unigene and/or its Affiliate as applicable. For avoidance of doubt, Unigene Know-How shall include all **, but does not include any **. Upon filing of the
corresponding **. Unigene Know-How shall be Confidential Information of Unigene as defined in Section 1.11 and shall be documented to the extent reasonable in written and/or electronic form. 
  
 “Unigene Patent Rights” means: (i) all patents and patent
applications in existence as of the Effective Date or during the Term of this Agreement claiming generically or specifically the ** that contain a Valid Claim which would be infringed by making, using, selling, offering for sale, or having made API
in the Territory or by the importation of API into the Territory; and (ii) any divisions, continuations, continuations-in-part, reissues, reexaminations, patents of additions, extensions, supplemental patent 

  

 - 5 - 

 
certificates, corresponding patents or patent applications in the same or other countries claiming priority from a patent a patent application in existence
as of the Effective Date, including those in patent applications or patents derived from Unigene Sole Improvements set forth in Exhibit D that contain a Valid Claim which would be infringed by **, or other governmental actions which extend the term
of any Valid Claim of the patent applications or patents in clause (i) above, and any substitutions, confirmations, registrations or revalidations of any of the foregoing, in each case which is owned or Controlled, in whole or part, by license,
assignment or otherwise by Unigene and/or its Affiliate as applicable as of the Effective Date. The Unigene Patent Rights are set forth in Exhibit E. 
  
 “Unigene Sole Improvements” means all improvements, whether or not severable, inventions, discoveries, processes, improved cell lines,
cell banks, clones, vectors, cassettes, separations, purifications and other knowledge, whether or not patentable (including patents, patent applications, divisions, continuations, continuation-in-part, reissues, reexaminations, extensions or
supplemental patent certificates), derived from Licensed Technology and made after the Effective Date of this Agreement **. 
  
 “U.S. Territory” means the United States of America and all of its territories and possessions, and shall include Puerto Rico.

  
 “Valid Claim” means a claim in an unexpired
and issued patent or pending patent application included in Unigene Patent Rights that has not been disclaimed, revoked or held invalid or unenforceable by a final unappealable decision of a government agency or court of competent jurisdiction, or
unappealed within the time limit allowed for appeal, or which has not been admitted to be invalid or unenforceable through reissue, reexamination or disclaimer or otherwise. 
  
 LICENSE GRANTS 
  
 License Grant from Unigene to Novartis. Subject to the terms and conditions of this Agreement, Unigene hereby grants to Novartis and its Affiliates
an exclusive license under the Licensed Technology to develop, manufacture, sell, use, import and export API, Intermediate and Amidating Enzyme in the Territory solely for the purpose of 
  
 developing, having developed, manufacturing, using, selling, having sold importing and exporting Novartis Drug Products
and/or 
  
 manufacturing and selling API to Unigene for use in
Unigene Drug Products, by Unigene its Affiliates, licensees or distributors. 
  
 Reservation of Rights to the Licensed Technology. 
  

 - 6 - 

             Unigene’s Oral
Product. Notwithstanding the exclusive license granted to Novartis in Section 2.1.1, Unigene shall have the right to 
  
 manufacture API, Amidating Enzyme and Intermediates for use in Unigene’s Oral Product needed until completion of **; 
  
 have manufactured API for use in Unigene’s Oral Product for commercial
sale exclusively by Novartis and/or its Affiliates, as per the terms of the Contract Manufacturing Agreement; 
  
 have manufactured API for use in Unigene’s Oral Product by a Third Party, **. 
  
 In the event that the Parties shall not **. 
  
             Other Unigene Products. Notwithstanding the
exclusive license granted to Novartis in Section 2.1.1, Unigene shall have the right to 
  
 develop, manufacture, have manufactured by a Joint Venture, sell, use, import and export API, Intermediates and Amidating Enzyme to the extent it is used in Other Unigene Products, it being understood that such Joint
Venture shall have the rights to manufacture API solely for use in Other Unigene Products; 
  
 have manufactured API for use in Other Unigene Products by Novartis and/or its Affiliates, as per the terms of the Contract Manufacturing Agreement; 
  
 have manufactured API for use in Other Unigene Products by a Third Party, **; 
  
 In the event that the Parties shall **. 
  
             **. Each Party and its Affiliates will, upon reasonable request, provide the other Party with a **. 
  
 Novartis Sublicensing Rights. 
  
             Novartis shall not be permitted to sublicense
the manufacture of API, Amidating Enzyme or Intermediates or provide any Third Party with access to ** included within the Licensed Technology without consent and prior written approval from Unigene, which approval shall be within Unigene’s
sole discretion. 
  
 Novartis shall have the right to sublicense
**, of Novartis Drug Products (but excluding **) without consent or approval from Unigene. 
  

 - 7 - 

 Improvement License Grants from Novartis to Unigene to manufacture API. 
  
             For Novartis Non-Severable Sole Improvements and Non-Severable Joint Improvements. 
  
 During the term of the Contract Manufacturing Agreement and/or this Agreement. During the term of the
Contract Manufacturing Agreement and/or this Agreement Novartis and/or its Affiliate as applicable shall upon implementation of Novartis Non-Severable Sole Improvements or Non-Severable Joint Improvements in its manufacture of API, Intermediates or
Amidating Enzyme, grant to Unigene, its Affiliates and/or Joint Ventures a **, to Novartis Non-Severable Sole Improvements solely to manufacture API, Intermediates or Amidating Enzyme. 
  
 Upon termination of the Contract Manufacturing Agreement and this Agreement. After both the Contract
Manufacturing Agreement and this Agreement have terminated any license granted to Unigene under Section 2.4.1.1 above shall be converted to a **, to Novartis Non-Severable Sole Improvements and Non-Severable Joint Improvements solely to manufacture
and have manufactured API, Intermediates or Amidating Enzyme. 
  
 Novartis and its Affiliates shall not at any time license Novartis Non-Severable Sole Improvements and/or Non-Severable Joint Improvements to any Third Party, and shall only employ Novartis Non-Severable Sole
Improvements and/or Non-Severable Joint Improvements to manufacture API, Intermediates or Amidating Enzyme for Novartis Drug Products or for Unigene. 
  
 For Novartis Severable Sole Improvements. 
  
 During the term of the Contract Manufacturing Agreement and this Agreement. During the term of the Contract Manufacturing Agreement and
this Agreement Novartis and/or its Affiliate as applicable shall upon implementation of Novartis Severable Sole Improvements in its manufacture of API, Intermediates or Amidating Enzyme, grant to Unigene, its Affiliates **, to Novartis Severable
Sole Improvements solely to manufacture API, Intermediates or Amidating Enzyme, **. 
  
 Upon termination of the Contract Manufacturing Agreement and/or the term of this Agreement. Upon termination of the Contract Manufacturing
Agreement and/or the term of this Agreement the Parties shall negotiate in good faith the terms of a ** solely to manufacture or have manufactured for Unigene, its Affiliates and/or Joint Ventures API, Intermediates or Amidating Enzyme. 

 
 Third Party Manufacturing. Unigene shall have the right ** is bound to
confidentiality with respect to any information shared in the implementation of such ** are bound by the terms and limitations of such licenses as set forth herein. 
  

 - 8 - 

 Improvement License Grants from Novartis to Unigene to manufacture proteins or peptides other than API.

  
 For Novartis Non-Severable Sole Improvements.
Upon **, the Parties shall negotiate in good faith the terms of an **. The right to ** will also be negotiated in good faith **. 
  
 For Novartis Severable Sole Improvements. Upon **, the Parties shall negotiate in good faith the terms of a **. ** will be negotiated on
an ** basis, unless agreed to the contrary in writing by the Parties. The right to ** will also be negotiated in good faith on an ** basis. 
  
 Licensed Technology Facilities. Prior to the commencement thereat, Novartis shall notify Unigene of each location at which Novartis will utilize
the Licensed Technology, with respect to the manufacture of API, Amidating Enzyme, Intermediates and/or Novartis Drug Products. 
  
 PAYMENTS 
  
 Initial Fee to Unigene. In partial consideration for the license to Licensed Technology granted to Novartis under Section 2.1 of this Agreement,
Novartis shall pay to Unigene three million five hundred thousand U.S. dollars (U.S. $ 3,500,000) within fifteen (15) days following execution of this Agreement, which amounts shall be non-refundable and not creditable against other amounts due
Unigene under this Agreement. 
  
 Milestone Payments to
Unigene. 
  
             Milestone Schedule for Novartis’ **. In partial consideration for the license to Licensed Technology granted to Novartis under Section 2.1 of this
Agreement, Novartis shall pay Unigene the amounts set forth below following the first achievement by Novartis its respective Affiliates or permitted sublicensees, as applicable and as the case may be, of each of the following milestones with respect
to the Novartis’ ** (“Milestones”): 
  

					
	 	  	 Milestone

	  	Amounts

	1.	  	The sixtieth (60th) day after initiation of the technology
transfer in accordance with the Technology Transfer Plan	  	U.S. $2,000,000
	2.	  	**	  	U.S. $**
	3.	  	**	  	U.S. $**
	4.	  	**	  	U.S. $**
	5.	  	**	  	U.S. $**

  

 - 9 - 

             For the avoidance of doubt,
the parties hereby acknowledge, ** to determine the Milestones listed in Section 3.2.1 shall only relate to **. 
  
 Novartis shall provide written notice of achievement of all Milestones other than Milestone 1 to Unigene within fifteen (15) days after
such event. For Milestone 1, Novartis shall notify Unigene in writing of the initiation of the Technology Transfer. 
  
 If Unigene has shipped API in accordance with the Clinical Supply Agreement, **. 
  
 Upon receipt of an invoice from Unigene specifying the
Milestone achieved, Novartis shall pay such Milestone within forty-five (45) days after receipt of such invoice. 
  
 Each such payment shall be made only one time, based upon achievement of a particular Milestone, regardless of how many times such
Milestone is achieved. 
  
 Each such payment
shall be non-refundable and non-creditable to Novartis against other amounts due to Unigene under this Agreement. 
  
 Unigene Licensed Technology Royalties. 
  
             Royalties on ** and **. In partial consideration of the license and rights
granted under the Licensed Technology hereunder, Novartis shall pay royalties to Unigene on ** and ** as follows: 
  
 ** of ** up to and including **; 
  
 ** of ** in excess of ** up to and including **; 
  

** of ** in excess of ** up to and including **; and 
  
 ** of ** in excess of **; 
  
 provided that, for purposes of this Section 3.3.1, achievement of the ** thresholds set forth shall be determined by **. The royalty rates
so determined shall **. 
  
 By way of examples: **. 
  

 - 10 - 

             Royalties on ** of **. In
partial consideration of the license and rights granted under the Licensed Technology hereunder, Novartis shall pay ** royalties to Unigene on **. 
  
             Unigene Licensed Technology Royalties. **. 
  
             Royalty Term. In accordance with Section 3.3.1 and 3.3.2 Novartis shall be obliged to pay royalties until the termination of this Agreement pursuant to Article
11 as follows: 
  
 Novartis shall pay royalties
as per Section 3.3.1 and 3.3.2 on a ** until **. 
  
 **. After the occurrence of the **. 
  
 **. **, during the term of this Agreement, ** it being agreed **. 
  
 Payment of Royalties. Payment of royalties shall be made forty five (45) days after the end of each Calendar Quarter on all Net Sales in the preceding quarter (“Quarterly Payment”). For each quarter, a
detailed report shall be delivered to Unigene forty-five (45) days after quarter end setting forth the total Net Sales by country in the Territory for the preceding Calendar Quarter. Such report shall include **. In the event that a ** is met during
a Calendar Quarter, **. 
  
 Single Royalty;
Non-Royalty Sales. No royalty shall be payable under Section 3.3.1 and 3.3.2 above with respect to sales of the Novartis Drug Products among Novartis its Affiliates and permitted sublicensees for resale to a Third Party. In no event shall more than
one such royalty be due to Unigene hereunder with respect to the sale of each Novartis Drug Products. 
  
 Third Party Fees or Royalties. Novartis shall be fully responsible for the payment of any additional royalties, license fees, milestones
and any and all other payments due to Third Parties that are required for Novartis, its Affiliates or licensees to develop, use, market, sell or import **. In such case, ** shall be responsible for the **. 
  
 Currencies. Payments under this Agreement shall be made in
United States Dollars. Net Sales for each country shall be converted into United States Dollars using Novartis’ then current standard exchange rate methodology ** for converting such local currency to the United States Dollar. 
  
 Manner of Payments. All sums due to Unigene under this
Agreement shall be payable in United States Dollars by bank wire transfer in immediately available funds to such bank account as Unigene shall designate. Novartis shall notify Unigene, in advance, as to the date and amount of any such wire transfer.

  

 - 11 - 

 For any payment made more than forty-five (45) days from the due date, Novartis shall pay interest at the ** on the
unpaid amount (unless a lower percentage is required by law). 
  
 Tax Withholding. Any tax, duty or other levy paid or required to be withheld by Novartis on account of royalties or other payments payable to Unigene under this Agreement shall be deducted from the amount of royalties
or payments otherwise due, provided that Novartis shall make such deductions only to the minimum extent required by the relevant jurisdiction. Novartis shall secure and send to Unigene proof of payment of any such taxes, duties or other levies
withheld and paid by Novartis for the benefit of Unigene, and cooperate at Unigene’s reasonable request to ensure that amounts withheld are reduced, creditable (or otherwise recoverable) to the fullest extent permitted by the relevant
jurisdiction. 
  
 Financial Records and Audits;
Unigene’s Right to Audit. Unigene, at its own cost, through an independent auditor (who will have executed a confidentiality agreement with Novartis) reasonably acceptable to Novartis, may inspect and audit the records of Novartis and its
Affiliates (including, without limitation, **), as may be necessary and for the sole purpose of verifying the accuracy of all financial and numerical information and calculations provided in the reports of Novartis relating to the sale of Novartis
Drug Product and any royalties due to Unigene under Section 3.3. Novartis shall, and shall cause its Affiliates (including, without limitation, **), provide access to such records during reasonable and regular business hours. Such audits shall not
be conducted more than once in any four (4) consecutive calendar quarters during the period that Novartis has an obligation to pay Royalties hereunder. The auditors shall report to Unigene only the amount of Royalty due. Unigene shall provide
Novartis with written notice of its election to inspect and audit the records related to the royalty due hereunder not less than thirty (30) days prior to the proposed date of review of such records by Unigene’s auditors. Novartis shall, and
shall cause its Affiliates (including, without limitation, **) to, maintain sufficient records to permit the inspection and auditing permitted hereunder for three (3) years after the date of each respective reporting period (or such longer period as
such records are required to be maintained by applicable law, rule, regulation or similar requirement). Novartis shall, and shall cause each of its Affiliates (including, without limitation, **) to, prepare its records and reports according to IAS
rules (International Accounting Standards) consistently applied. Should the auditor find any underpayment of royalties by Novartis, Novartis shall promptly pay Unigene the amount of such underpayment, plus interest ** per annum or portion thereof on
the amount of any underpayment from the date payment was due, and shall reimburse Unigene for the cost of the audit should such underpayment equal or exceed ** of royalties paid in any Calendar Quarter. 
  
 Bundling. When a Novartis Drug Product is bundled with one
or more other Novartis Drug Products or one or more other products sold by Novartis which are not Novartis Drug Products, the selling price for each such Novartis Drug Product shall be the ** sold to a Third Party in an arm’s length
transaction. However, in 

  

 - 12 - 

 
no event shall Novartis be constrained in pricing any Novartis Drug Product and in no event shall Novartis be required to reveal to Unigene the pricing of
any Novartis Drug Product or any other product sold by Novartis as part of the bundle. 
  
 TECHNOLOGY TRANSFER 
  
 Unigene Know-How and Material Transfer. Upon written notice from Novartis Unigene shall use its reasonable commercial efforts to promptly transfer, or cause to be transferred to Novartis and/or its designated Affiliate a copy of
Unigene Know-How reduced to written or electronic form and all Process Transfer Information that is reasonably required by Novartis and or its Affiliates in accordance with the Technology Transfer Plan, it being understood that initiation of the
technology transfer and locations as determined in the Technology Transfer Plan in Exhibit C attached hereto may be adjusted by Novartis as needed, it being further understood, that provided the Licensed Technology shall be transferred to
Novartis’ Affiliate **, the locations as determined in Exhibit C shall remain unchanged. Unigene Know-How shall remain the exclusive property of Unigene and shall be deemed to be Unigene’s Confidential Information. 
  
 Assistance. In accordance with the Technology Transfer Plan and upon
written request by Novartis and/or its Affiliates Unigene shall provide the Novartis Affiliate with technical support with respect to the transfer, implementation and use of the Unigene Know-How in the manufacture of API, Amidating Enzyme and
Intermediates (the “Technical Support”). The Technical Support as agreed on in the Technology Transfer Plan will be provided ** in connection with the provision of the Technical Support. The Technical Support will be provided at the
locations designated in the technology transfer plan, and shall include access to documents and key personnel necessary to allow Novartis to develop the expertise to manufacture, and access and visits to the Unigene facilities to observe the
manufacturing; provided, however, that Technical Support provided at Unigene’s facilities shall not be permitted to interfere with the day-to-day operations thereof. It is understood, that the Technical Support to be provided by Unigene **
shall be limited to **, provided that such man days may be reallocated by Novartis and/or its Affiliates to different tasks of the Technology Transfer Plan as needed, except as to the designated locations to provide the Technical Support, which
shall remain unchanged. All Technical Support shall be provided in English. All information provided by Unigene in carrying out the Technical Support shall be deemed to be Unigene Know-How. 
  
 Technical Support beyond the Technology Transfer Plan. It is
understood that activities, scale, locations, timing and man days as listed in the Technology Transfer Plan are best estimates only and may require adaptation as well as additional activities and additional man days by Unigene. All costs and out
-of-pocket expenses incurred by Unigene for Technical Support requested by Novartis in addition to the Technical Support agreed on in the Technology Transfer Plan shall be borne by 

  

 - 13 - 

 
Novartis. Such additional Technical Support shall be reimbursed at the rate of Euro ** per man-day with each man-day equal to at least eight (8) working
hours. 
  
 Cost of Technology Transfer. All other cost of
such technology transfer shall be borne by Novartis. If the parties come to an agreement on the Contract Manufacturing Agreement as set forth in Section 5.2.2, then all costs of such technology transfer shall be borne by Novartis, whether or not
Novartis continues to develop Novartis’ Oral Product. Termination of this Agreement shall not relieve the obligation of Novartis to bear all such costs, provided the parties have agreed on the Contract Manufacturing Agreement pursuant to
Section 5.2.2. below. 
  
 SUPPLY AND MANUFACTURE 

 
 Unigene Supply to Novartis. Unigene hereby agrees to manufacture,
sell and deliver API for use in the development of Novartis’ Oral Product pursuant to the Clinical Supply Agreement attached hereto as Exhibit A, which terms shall be incorporated herein. 
  
 Novartis Supply to Unigene. 
  
             Clinical and Commercial Supply of API for use in Unigene Drug Products. Within ** days following Effective Date, which may be extended by mutual agreement (the
“Negotiation Period”) Novartis and Unigene shall negotiate in good faith toward concluding a clinical supply agreement (“Product Supply Agreement”) and a commercial supply agreement (the “Contract Manufacturing
Agreement”). Such Product Supply Agreement and Contract Manufacturing Agreement shall incorporate the principles as set forth in Exhibits B, C and F, provided, however, that Exhibits B, C and F shall be legally nonbinding to both parties and
are subject to final senior management approval of both parties. 
  
 In the event that **, shall be appointed by Novartis to be the party to the Contract Manufacturing Agreement, the Contract Manufacturing Agreement (Exhibit B), the Product Supply Agreement (Exhibit F) and the
Technology Transfer Plan (Exhibit C) shall be binding on both parties, provided, however, that the initiation of the Technology Transfer Plan and the Obligated Date in the Product Supply Agreement shall be adjusted as needed. 
  
 In the event that no Contract Manufacturing Agreement shall
be concluded and executed within the Negotiation Period despite good faith negotiations, the license granted to Novartis under Section 2.1 (b) shall terminate. 
  

 - 14 - 

 INTELLECTUAL PROPERTY 
  
 Ownership and Inventorship of Sole and Joint Improvements. 
  
             Ownership. Unigene shall solely own all right, title, and interest in all Unigene Sole Improvements. Novartis and or its Affiliates shall solely own all right,
title, and interest in all Novartis Non-Severable Sole Improvements and Novartis Severable Sole Improvements. Each Party shall own an undivided right, title, and interest, as defined under the applicable U.S. law, in any Joint Improvements and
Non-Severable Joint Improvements, and whether patentable or not patentable subject to the provisions of this Agreement. Each Party shall reasonably promptly disclose to the other Party all Improvements made by it. Each Party shall notify the other
Party if it wishes to file a patent application concerning an Improvement no later than thirty (30) days before the anticipated date of such filing. If an express grant of rights from one Party to the other is required in any country to give full
force and effect to this provision, the Parties shall execute any instrument necessary to accomplish the intent of the foregoing grant. 
  
 Inventorship. Inventorship and, subject to this Agreement the rights of ownership, of inventions and other intellectual property rights
conceived and/or reduced to practice in connection with the development activities hereunder shall be determined in accordance with the laws of the United States. It is understood that, except as otherwise provided herein, neither Party shall have
any obligation to account to the other for profits, or to obtain any approval of the other Party to license, assign, mortgage or exploit a Joint Improvement by reason of joint ownership of any such intellectual property, and may otherwise undertake
all activities a sole owner might undertake with respect to such Joint Improvement without the consent and without accounting to the other joint owner, except as otherwise provided in this Agreement or as the Parties may otherwise agree in writing.

  
 Filing, Prosecution, Maintenance and Enforcement of Patents.

  
 Licensed Technology. If Unigene elects not to
prosecute or maintain such patent applications or ensuing patents or claims included in Unigene Patent Rights in any country of the Territory, Unigene shall give Novartis notice thereof within a reasonable period prior to allowing such patent
applications or patents or such claims encompassed by such patent applications or patents to lapse or become abandoned or unenforceable, and Novartis shall thereafter have the right, at its sole expense, to prepare, file, prosecute and maintain such
patent applications and patents or divisional applications related to such claims encompassed by such patent applications or patents in countries of Novartis’ choice throughout the world. Patents which Novartis has assumed the prosecution and
maintenance of shall no longer be included in the Unigene Patent Rights. 
  

 - 15 - 

 Sole Improvements. Each of Unigene and Novartis (“Filing Party”) shall be
responsible for the reasonable and diligent filing and prosecution of all patent applications relating to its Sole Improvements under this Agreement, but no party shall have an obligation to file an application relating to such Sole Improvement.
Each Filing Party shall bear the cost and responsibility for the filing and prosecution of all such patent applications. The Filing Party shall provide the other Party with (a) a brief summary of the Sole Invention, and (b) the main claim at least
thirty (30) days before the patent application is planned to be filed. The other Party may comment and make recommendations about content and filing strategy, which comments the Filing Party shall take under consideration. The Filing Party shall
also keep the other Party informed of all material issues relating to the preparation, filing and prosecution of such patent applications. Neither Party shall file any patent application which shall lead to the disclosure of the other Party’s
Confidential Information unless the other Party has first agreed in writing to the filing. If Novartis decides not to continue to prosecute or maintain a patent application or patent in a country for Novartis Non-Severable Sole Improvements after
such patent or patent application has been published and Unigene wishes to do so, then the Novartis Non-Severable Sole Improvement and resulting patent applications and patents shall be assigned to Unigene and such patent applications and patents
shall become part of Unigene Patent Rights and shall no longer be a Novartis Non-Severable Sole Improvement. Prior to publication, Novartis and/or its Affiliates will have no obligation to assign such patents or patent applications to Unigene.

  
 Joint Improvements. In the case of Joint
Improvements **, the Parties shall decide whether or not to secure patent protection and which Party shall bear the primary responsibility for preparing, filing and prosecuting the Patent applications resulting there from. Patent-related expenses
for Joint Improvements **. If the Parties cannot agree which Party shall bear the primary responsibility for preparing, filing, and prosecuting Patent Applications resulting from a Joint Invention **, then counsel mutually agreeable to the Parties
shall prepare, file and prosecute the patent applications and the Parties shall ** related thereto. Each Party shall promptly render all necessary assistance reasonably requested by the other Party in applying for and prosecuting the patent
applications. Neither Party shall file any patent application on Joint Improvements ** which shall lead to the disclosure of the other Party’s Confidential Information, unless the other Party has first agreed in writing to the filing. If a
Party responsible for the prosecution or maintenance of a patent or patent application directed to a Joint Improvement ** elects not to continue prosecution or maintenance of such patent or patent application, the Party will give the other Party
notice of such election within a reasonable period prior to allowing such patent or patent application to lapse or become unenforceable, and the other Party will have the right to continue prosecution or maintenance of such patent or patent
application; and if ** decides not to file a patent application for a ** shall be permitted to do so. If a Party (the “Relinquishing Party”) declines to pay its share of patent-related expenses for any patent application or patent directed
to a Joint Improvement **, the other Party may assume payment of the Relinquishing Party’s share of the patent-related expenses, and 

  

 - 16 - 

 
the Relinquishing Party will assign title to such patent application or patent to Party assuming payment. 
  
 Enforcement of Unigene Patent Rights. Subject to Section
6.2.5 below, in the event that a Party learns that any Unigene Patent Rights necessary for the manufacture, use and/or sale of API are infringed or misappropriated by a Third Party in any country in the Territory, or is subject to a declaratory
judgment action arising from such infringement in such country, such Party shall promptly notify the other Party hereto. Unigene shall have the initial right (but not the obligation) to enforce such Unigene Patent Rights by initiating an appropriate
suit or action against such Third Party, or defend any declaratory judgment action with respect thereto, at its expense, and to use Novartis’ name in connection therewith; provided that such use without Novartis’ written consent may only
occur where necessary or indispensable for Unigene to bring such suit or action. Novartis shall have the right to join in any suit or action initiated by Unigene within 90 days of the bringing of such suit or action by Unigene. Novartis may retain
counsel of its choosing, at Novartis’ sole expense, or Novartis may utilize the counsel selected and directed by Unigene and share equally in the costs associated therewith. In the event that Unigene fails to initiate a suit or action to
enforce such Unigene Patent Rights against such a Third Party in any jurisdiction in the Territory within ninety (90) days after notification of such infringement, Novartis may initiate such suit or action in its own name with regard to the
applicable Unigene Patent Rights against such infringement, at the expense of Novartis, and to use Unigene’s name in connection therewith; provided that such use without Unigene’s written consent may only occur where necessary or
indispensable for Novartis to bring such suit or action. If Novartis initiates such a suit or action, Unigene will have the right to join within ninety (90) days of the bringing of such suit or action by Novartis. Unigene may retain counsel of its
choosing, at Unigene’s sole expense, or Unigene may utilize the counsel selected and directed by Novartis and share equally in the costs associated therewith. If only one Party is prosecuting a suit or action, the Party involved in the suit or
action (the “Enforcing Party”), shall keep the other Party hereto reasonably informed of the progress of any such action. Unigene and/or Novartis shall recover their respective actual out-of-pocket expenses, or equitable proportions
thereof, associated with any litigation or settlement thereof from any recovery made in a suit or action to which they were an active Party. Any excess amount recovered shall be allocated as follows: if the suit is joined by both Parties, the excess
amount recovered is divided equally, and if only one Party brings the suit (the “Litigating Party”) and is not joined by the other Party, then only the Litigating Party shall receive the excess amount recovered. 
  
 Enforcement of Joint Improvement Patent Rights.
Notwithstanding anything to the contrary in Section 6.2.4 above, in the event that any patent that is jointly owned by Unigene and Novartis under Section 6.1.1 of this Agreement is infringed or misappropriated by a Third Party, Novartis and Unigene
shall discuss whether, and, if so, how, to enforce such jointly owned patent or defend such jointly owned patent in an infringement action, declaratory judgment or other proceeding. In the event only one Party wishes to participate in such
proceeding, it shall have the right 

  

 - 17 - 

 
to proceed alone, at its expense, and may retain any recovery; provided, however, that at the request and expense of the participating Party, the other Party
agrees to cooperate and join in any proceedings in the event that a Third Party asserts that the coowner of such Joint Improvement patent rights or Non-Severable Joint Improvement patent rights is necessary or indispensable to such proceedings. The
participating Party shall keep the other Party hereto reasonably informed of the progress of such proceeding. Damages recovered by a Party or Parties in an action under this Section 6.2.5 are to be allocated according to the scheme set out in
Section 6.2.4, above. 
  
 Infringement Claims. If
the manufacture, use, or sale of API in the Territory pursuant to this Agreement results in any claim, suit or proceeding alleging patent infringement against Unigene or Novartis, or their Affiliates, such Party shall promptly notify the other Party
hereto. If Novartis or its Affiliate is not named as a Party in such a claim, suit or proceeding, Novartis or its Affiliate may, at its own expense and through counsel of its own choice, seek leave to intervene in such claim, suit or proceeding.
Unigene agrees not to oppose such intervention. If Novartis or its Affiliate, and not Unigene, is named as a Party to such claim, suit or proceeding, Novartis shall have the right to control the defense and settlement of such claim, suit or
proceeding, at its own expense, using counsel of its own choice. Unigene, however, at its own expense and through counsel of its own choice, may seek to intervene if the claim, suit or proceeding relates to the commercialization of the API in the
Field, and in such event, Novartis and its Affiliates agree not to oppose such intervention. If Novartis or its Affiliate is named as a Party, or if Novartis or its Affiliate is successful in intervening in actions brought against Unigene or its
Affiliate, and Unigene shall, at any time, tender its defense to Novartis or its Affiliate, then Novartis shall defend Unigene in such claim, suit or proceeding, at Novartis’ own expense and through counsel of its own choice, and Novartis shall
control the defense and settlement of any such claim, suit or proceeding; provided, Novartis shall not enter into any agreement which (i) extends or purports to exercise Novartis’ rights under Unigene’s Licensed Technology beyond the
rights granted pursuant to this Agreement, (ii) makes any admission regarding (a) wrongdoing on the part of Unigene, or (b) the invalidity, unenforceability or absence of infringement of any Unigene Patent Rights or patent claiming a Joint
Invention, without the prior written consent of Unigene, which consent shall not be unreasonably withheld. The Parties shall cooperate with each other in connection with any such claim, suit or proceeding and shall keep each other reasonably
informed of all material developments in connection with any such claim, suit or proceeding. 
  
 Litigation Activities Update. The Parties shall keep one another informed of the status of and of their respective activities regarding
any litigation or settlement thereof concerning API, provided however that no settlement or consent judgment or other voluntary final disposition of any suit defended or action brought by a Party pursuant to this Article 6 may be entered into
without the written consent of the other Party, which consent shall not be unreasonably withheld or delayed. 
  

 - 18 - 

 REPRESENTATIONS, WARRANTIES AND COVENANTS 
  
 Warranties. 
  
             Unigene. Unigene warrants and represents to Novartis that: 
  
 as of the Effective Date, and except as otherwise disclosed to Novartis, it has full Control of the Licensed Technology to grant the
rights and licenses granted hereunder, and that it otherwise has the full right and authority to enter into this Agreement; 
  
 as of the Effective Date, there are no existing or threatened actions, suits or claims pending against it with respect to the Licensed
Technology or its right to enter into and perform its obligations under this Agreement; 
  
 as of the Effective Date, to the best of Unigene’s knowledge, there are no existing intellectual property rights that would be
infringed by Novartis’ practice of the Licensed Technology in the Territory or by the developing, making, use or importation by Novartis of API in the Territory; 
  
 as of the Effective Date, it has not granted, and will not grant during the Term of this Agreement, any
right, license or interest in or to the Licensed Technology that is in conflict with the rights or licenses granted under this Agreement, nor as of the Effective Date, has it encumbered any Unigene Know-How and/or Unigene Patent Rights, except as
set forth on Exhibit G, attached hereto and incorporated herein; 
  
 as of the Effective Date, it has no knowledge from which it concludes that the process by which it manufactures API would infringe patent rights of Third Parties in the Territory; 
  
 there is nothing in any Third Party agreement Unigene has
entered into as of the Effective Date, which, in any way, will limit Unigene’s ability to perform all of the obligations undertaken by Unigene hereunder, and that it will not enter into any agreement after the Effective Date under which Unigene
would incur any such limitations; 
  
 it has not
intentionally concealed from Novartis the existence of any pre-clinical or clinical data or information concerning API, or anticipated components thereof, which suggests that there may exist quality, toxicity, safety and/or efficacy concerns which
may materially impair the utility and/or safety of API, or anticipated components thereof; and 
  
 it will perform all of its obligations under any Third Party agreements necessary to maintain Unigene Patent Rights as set out in Appendix
E, and 

  

 - 19 - 

 
will maintain such agreements in full force and effect and will not terminate or amend such agreements without Novartis’ written approval. 

 
 Novartis. Novartis warrants and represents to Unigene
that: 
  
 as of the Effective Date, it has the
full right and authority to enter into this Agreement; 
  
 as of the Effective Date, there are no existing or threatened actions, suits or claims pending against it with respect to its right to enter into and perform its obligations under this Agreement; 
  
 as of the Effective Date, it has not granted, and it will
not employ or license, right, title or interest in or to the Novartis Non-Severable Improvements, the Novartis Severable Sole Improvements and/or Joint Improvements which is in conflict with the rights or licenses granted to Unigene under this
Agreement, or is inconsistent with this Agreement and 
  
 there is nothing in any Third Party agreement Novartis has entered into as of the Effective Date, which, in any way, will limit Novartis’ ability to perform all of the obligations undertaken by Novartis hereunder, and that it will not
enter into any agreement after the Effective Date under which Novartis would incur any such limitations. 
  
 CONFIDENTIALITY AND EXCHANGE OF INFORMATION 
  
 Confidential Information. Except as expressly provided herein, the Parties agree that, for the Term of this Agreement and for ten (10) years
thereafter, the receiving Party shall keep completely confidential and shall not publish or otherwise disclose and shall not use for any purpose except for the purposes contemplated by this Agreement any Confidential Information furnished to it by
the disclosing Party hereto pursuant to this Agreement, except that to the extent that it can be established by the receiving Party by competent proof that such Confidential Information: 
  
             was already known to the receiving Party,
other than under an obligation of confidentiality, at the time of disclosure; 
  
 was generally available to the public at the time of its disclosure to the receiving Party; 
  
 became generally available to the public after its disclosure and other than through any act or omission of the receiving Party in breach of this
Agreement; 
  

 - 20 - 

             was independently
developed by the receiving Party without reference to any information or materials disclosed by the disclosing Party; or 
  
 was subsequently disclosed to the receiving Party by a person other than a Party without breach of any legal obligation to the disclosing
Party. 
  
 The foregoing obligations shall be in addition to, and not in lieu of,
the obligations of confidentiality set forth in the Confidentiality Agreement. 
  
 Permitted Disclosures. 
  
             Each Party hereto may disclose the other’s Confidential Information to the extent such disclosure is reasonably necessary in connection with the conduct of
the development activities to be conducted hereunder, prosecuting or defending litigation, complying with applicable governmental regulations or otherwise submitting information to tax or other governmental authorities or conducting clinical trials,
provided that if a Party is required to make any such disclosure of another Party’s Confidential Information, it will give reasonable advance notice to the latter Party of such disclosure and, will use its commercially reasonable best efforts
to secure confidential treatment of such information prior to its disclosure (whether through protective orders or otherwise). In no event shall Novartis, its Affiliate or any Third party include Unigene Confidential Information in any patent
application without written consent from Unigene, nor disclose such information to any non-governmental Third Party unless the Third Party has entered into a Confidentiality Agreement at least as protective as this Article 8. Similarly, in no event
shall Unigene, its Affiliate or any Third Party include Novartis Confidential Information in any patent application without written consent from Novartis, nor disclose such information to any non-governmental Third Party unless the Third Party has
entered into a Confidentiality Agreement at least as protective as this Article 8. 
  
 Notwithstanding anything in this Agreement or in any other agreement to the contrary, each Party to this Agreement (and each employee,
representative, or other agent of each Party) may (but is not required to) disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transaction contemplated by this Agreement and the other
agreements and instruments to be executed in connection herewith, as of the earlier of (a) the date of public announcement of discussions relating to the transactions contemplated by this Agreement, (b) the date of public announcement of such
transactions, or (c) the date of the execution of the Agreement to enter into such transactions; provided, however, that such disclosure shall be prohibited to the extent required to comply with any applicable federal or state securities laws; and
provided further that the confidentiality provisions of this Agreement and the other agreements and instruments relating to the transactions between the Parties shall continue to apply to information that is irrelevant to understanding the tax
treatment or tax structure of the transactions contemplated hereby and thereby (including, without limitation, the names and other identifying details 

  

 - 21 - 

 
of any Party to this Agreement). The preceding sentences are intended to cause the transaction contemplated herein to be treated as not having been offered
under conditions of confidentiality for purposes of Section 1.6011-4(b)(3) (or any successor provision) of the Internal Revenue Code (the “Code”) and shall be construed in a manner consistent with such purpose. Each Party recognizes that
the privilege each has with respect to the confidentiality of the transaction contemplated by this Agreement or the confidentiality of a communication relating to such transaction, including a confidential communication with its attorney or with a
federally authorized tax practitioner under Section 7252 of the Code, is not intended to be waived by the foregoing. 
  
 Novartis and its Affiliates hereby agree to be parties to the Confidentiality Agreement described in Section 1.10 as of its effective date. 
  
 Public Announcements. No public announcement or other disclosure to
Third Parties concerning the existence of, terms, or subject matter of this Agreement shall be made, either directly or indirectly, by any Party to this Agreement, except as may be legally required or as may be required for recording purposes,
without first obtaining the approval of the other Party and agreement upon the nature and text of such announcement or disclosure. The Party desiring to make any such public announcement or other disclosure (including, without limitation, those
which are legally required or may be required for recording purposes) shall inform the other Party of the proposed announcement or disclosure in reasonably sufficient time prior to public release, which shall be at least three (3) business days
prior to release of such proposed announcement or disclosure, and shall provide the other Party with a written copy thereof, in order to allow such other Party to comment upon such announcement or disclosure. Each Party agrees that it shall
cooperate fully with the other with respect to all disclosures regarding this Agreement to the Securities Exchange Commission and any other governmental or regulatory agencies, including, without limitation, requests for confidential treatment of
proprietary information of either Party included in any such disclosure. Notwithstanding the foregoing, Novartis hereby agrees that Unigene shall be entitled to issue a press release in the form attached hereto as Exhibit H without the need for
further approval by Novartis. 
  
 Publications. Neither
Party shall submit for written or oral publication any manuscript, abstract or the like which includes data or other information containing the other Party’s Confidential Information without first obtaining the prior written consent of the
other Party, which consent shall not be unreasonably withheld, and shall be promptly given or refused. In no event shall either party be required to approve publication of its Know-How or other Confidential Information. Nothing herein shall be
construed to prevent Novartis from disclosing on a need to know basis any information received from Unigene hereunder to an Affiliate, Third Party distributor, research or clinical contractor of Novartis, provided, such recipient shall be bound by
confidentiality obligations as set out herein with respect to Confidential Information. Nothing herein shall be construed to prevent Unigene from disclosing any information on a need to 

  

 - 22 - 

 
know basis received from Novartis or its Affiliate to a Third Party distributor, research or clinical contractor, licensee or potential licensee of Unigene
provided such recipient shall be bound by confidentiality provisions set out herein with respect to Confidential Information. 
  
 Bankruptcy. All Confidential Information disclosed by one Party to the other shall remain the intellectual property of the disclosing Party. In the
event that a court or other legal or administrative tribunal, directly or through an appointed master, trustee or receiver, assumes partial or complete control over the assets of a Party to this Agreement based on the insolvency or bankruptcy of
such Party, the bankrupt or insolvent Party shall promptly notify the court or other tribunal (i) that Confidential Information received from the other Party under this Agreement remains the property of the other Party, and (ii) of the
confidentiality obligations under this Agreement. In addition, the bankrupt or insolvent Party shall, to the extent permitted by law, take all steps necessary or desirable to maintain the confidentiality of the other Party’s Confidential
Information and to ensure that the court, other tribunal or appointee maintains such information in confidence in accordance with the terms of this Agreement. 
  

INDEMNIFICATION 
  
 Indemnification of Novartis. Unigene shall indemnify and hold harmless Novartis and its respective Affiliates, directors, officers, employees,
agents and counsel, and the successors and assigns of the foregoing (the “Novartis Indemnitees”), from and against any and all liabilities, damages, losses, costs or expenses (including reasonable attorneys’ and professional fees and
other expenses of litigation and/or arbitration) resulting from a claim, suit or proceeding brought by a Third Party against a Novartis Indemnitee, to the extent arising from or occurring as a result of (a) Unigene’s material breach of this
Agreement, or (b) the research, development, commercialization and/or marketing of any Unigene Drug Products by Unigene, its Affiliates, designees, sublicensees and Joint Ventures, except, in each case, to the extent caused by the negligence or
willful misconduct of Novartis (including their respective Affiliates and sublicensees) or to the extent that Novartis is obligated to indemnify Unigene under Section 9.2 below or pursuant to the Clinical Supply Agreement or Contract Manufacturing
Agreement. It is understood that the foregoing indemnity does not include any lost profits or consequential damages. 
  
 Indemnification of Unigene. Novartis shall indemnify and hold harmless Unigene and its Affiliates and their respective directors, officers,
employees, agents and counsel and the successors and assigns of the foregoing (the “Unigene Indemnitees”), from and against any and all liabilities, damages, costs or expenses (including reasonable attorneys’ and professional fees and
other expenses of litigation and/or arbitration) brought by a Third Party against a Unigene Indemnitee, arising from or occurring as a result of: (a) the conduct of clinical trials and development activities 

  

 - 23 - 

 
related to API, Amidating Enzyme, Intermediates and/or Novartis Drug Products by either Novartis or its Affiliates or sublicensees, (b) the research,
development, manufacture, marketing and/or commercialization of any Novartis Drug Product by Novartis or its Affiliates or sublicensees (including without limitation, Novartis Drug Product liability claims, (c) the use of the Licensed Technology by
Novartis or its Affiliates or sublicensees except as is expressly authorized pursuant to this Agreement, or (d) any material breach of this Agreement by Novartis except, in each case, to the extent caused by the negligence or willful misconduct of
Unigene, its Affiliates, designees, sublicensees and Joint Ventures or to the extent that Unigene is obligated to indemnify Novartis under Section 9.1. It is understood that the foregoing indemnity does not include any lost profits or consequential
damages. 
  
 Procedure. A Party (the
“Indemnitee”) that intends to claim indemnification under this Article 9 shall promptly notify the other Party (the “Indemnitor”) in writing of any loss, claim, damage, liability or action in respect of which the Indemnitee or
any of its Affiliates, sublicensees or their directors, officers, employees, agents or counsel intend to claim such indemnification, and the Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so desires, to assume
the defense thereof with counsel mutually satisfactory to the Parties. The indemnity agreement in this Article 9 shall not apply to amounts paid in settlement of any loss, claim, damage, liability or action if such settlement is made without the
consent of the Indemnitor, which consent shall not be withheld unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action, if prejudicial to its ability to defend such
action, shall relieve such Indemnitor of any liability to the Indemnitee under this Article 9. At the Indemnitor’s request, the Indemnitee under this Article 9, and its employees and agents, shall cooperate fully with the Indemnitor and its
legal representatives in the investigation and defense of any action, claim or liability covered by this indemnification and provide full information with respect thereto. 
  
 DISCLAIMER OF WARRANTIES 
  
 THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY SET FORTH HEREIN. UNIGENE AND NOVARTIS DISCLAIM ALL
OTHER REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO THE LICENSED TECHNOLOGY, EACH OF THEIR RESEARCH, DEVELOPMENT AND COMMERCIALIZATION EFFORTS HEREUNDER, INCLUDING, WITHOUT LIMITATION, WHETHER THE UNIGENE AND/OR THE
NOVARTIS DRUG PRODUCTS CAN BE SUCCESSFULLY DEVELOPED OR MARKETED, THE ACCURACY, PERFORMANCE, UTILITY, RELIABILITY, TECHNOLOGICAL OR COMMERCIAL VALUE, COMPREHENSIVENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE WHATSOEVER OF THE UNIGENE
AND/OR THE NOVARTIS DRUG PRODUCTS. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, IN NO EVENT SHALL EITHER UNIGENE OR NOVARTIS BE LIABLE TO THE OTHER FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES UNDER OR INCIDENTAL TO THIS
AGREEMENT, ITS PERFORMANCE OR THE NEGOTIATIONS LEADING UP TO ITS ENTRY, INCLUDING BUT NOT LIMITED TO LOSS OF PROFITS, LOSS OF OR DAMAGE TO GOODWILL OR TO 

  

 - 24 - 

 
ANY OTHER EXPECTATION BENEFIT, OR LIABILITY TO THIRD PARTIES, EXCEPT AS PROVIDED FOR IN ARTICLE IX. 
  
 TERM AND TERMINATION 
  
 Term. This License Agreement shall be effective as of the Effective
Date. Unless this License Agreement is otherwise terminated earlier pursuant to provisions of this Article 11, this License Agreement shall continue in full force and effect until date which first occurs of (a) the date Novartis and its Affiliates
cease to manufacture API for use in Novartis Drug Products and in Unigene Drug Products or (b) the date Novartis and/or its Affiliates decide not to manufacture API. 
  
 Termination for Material Breach. Either Party may terminate this License Agreement in the event the other Party
and/or its Affiliates and/or its Joint Ventures have materially breached or defaulted in the performance of any of its obligations hereunder, and if such default is not corrected within sixty (60) days after receiving written notice from the other
Party with respect to such default, such other Party shall have the right to terminate this Agreement by giving written notice to the Party in default, provided the notice of termination is given within one (1) year of when the Party giving notice
knew or should have known of the default and prior to correction of the default; provided that the time period for providing such notice of termination shall be extended for so long as the Parties are engaged in good faith negotiations to resolve
the situation. Notwithstanding the above, in the case of a failure of Novartis to pay any Royalty, and/or Milestone, and/or upfront payment due hereunder, the period for cure of any such failure to pay following written notice from Unigene thereof
shall be thirty (30) days and, unless payment is made by Novartis within such period or unless Novartis has notified Unigene that a good faith dispute exists regarding Novartis’ failure to pay, the termination shall become effective at the end
of such thirty (30) day period. 
  
 Termination for Insolvency;
Retention of License. If voluntary or involuntary proceedings by or against a Party are instituted in bankruptcy under any insolvency law, or a receiver or custodian is appointed for such Party, or proceedings are instituted by or against such
Party for corporate reorganization or the dissolution of such Party, which proceedings, if involuntary, shall not have been dismissed within sixty (60) days after the date of filing, or if such Party makes an assignment for the benefit of creditors,
or substantially all of the assets of such Party are seized or attached and not released within sixty (60) days thereafter, the other Party may immediately terminate this Agreement effective upon notice of such proceeding. Notwithstanding the
bankruptcy of a Party, or the impairment of performance by a Party of its obligations under this Agreement as a result of bankruptcy or insolvency of such Party, and subject to such Party’s rights to terminate this Agreement for reasons other
than bankruptcy or insolvency as expressly provided in this Agreement, the other Party shall be entitled to retain the licenses under the terms and conditions granted herein. 
  

 - 25 - 

 General Effect of Termination. 
  
             Accrued Obligations. Termination of this
Agreement for any reason shall not release any Party hereto from any liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination, nor preclude either Party
from pursuing any rights and remedies it may have hereunder or at law or in equity which accrued or are based upon any event occurring prior to such termination. 
  
 Return of Materials. Upon any termination of this Agreement except as for termination by Novartis according
to Section 11.2, Novartis shall promptly return to Unigene all of Unigene’s Confidential Information in Novartis’ possession or control (except for one copy of Confidential Information which is to be retained in the confidential files of
Novartis for record purposes only). Upon any termination of this Agreement, Unigene shall promptly return to Novartis all of Novartis’ Confidential Information in Unigene’s possession or control (except for one copy of Confidential
Information which is to be retained in the confidential files of Unigene for record purposes only). 
  
 Stock on Hand. In the event that this Agreement is terminated for any reason, other than upon the occurrence of a material breach by
Novartis pursuant to Section 11.2, after commencement of commercial sales of Novartis Drug Products by Novartis and/or its Affiliates and sublicensees, Novartis and its Affiliates and sublicensees shall have the right to sell (as to Novartis Drug
Product only) or otherwise dispose of the stock of any Novartis Drug Products then on hand for up to six (6) months after the date of termination, subject to Article 3 and the other applicable terms of this Agreement, including, but not limited to,
royalty obligations. If Unigene terminates this Agreement pursuant to Section11.2, Novartis and its Affiliates and sublicensees shall immediately cease all sales of Novartis Drug Products. 
  
 Termination of Licenses for material breach by Novartis.
Subject to Section 11.4.3, upon termination of this Agreement by Unigene due to an uncured material breach by Novartis pursuant to Section 11.2, the licenses granted to Novartis under this Agreement shall terminate. 
  
 Material Breach by Unigene. In the event of disclosure of
Licensed Technology in violation of this Agreement and/or the Contract Manufacturing Agreement by Unigene to a Third Party so as to enable a Third Party to manufacture API for commercial purposes, and at the sole option of Novartis all provisions of
this Agreement shall remain in full force and effect with the exception of Sections ** which shall terminate with immediate effect, provided Novartis does not terminate the Agreement as per Section 11.2. In all other events of a material breach by
Unigene, and provided Novartis, in its sole discretion, does not terminate the Agreement as per Section 11.2, all provisions of this Agreement shall remain in full force and effect, with 

  

 - 26 - 

 
the exception that the **, and Sections **, provided Novartis does not terminate the Agreement accordance with Section 11.2. 
  
 Bankruptcy Provisions. All rights to the Licensed Technology
granted to Novartis under Article 2 hereof are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(52) of the U.S.
Bankruptcy Code. The Parties agree that Novartis, as licensee of such rights, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code, subject to performance by Novartis of its obligations under this
Agreement. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Unigene under the U.S. Bankruptcy Code, Novartis shall be entitled to a complete duplicate of (or complete access to, as
appropriate) any such intellectual property and all embodiments of such intellectual property, and same, if not already in its possession, shall be promptly delivered to Novartis (a) upon any such commencement of a bankruptcy proceeding upon written
request therefore by Novartis, unless Unigene elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of Unigene upon written request
therefore by Novartis, provided, however, that upon Unigene’s (or its successor’s) written notification to Novartis that Unigene is again willing and able to perform all of its obligations under this Agreement, Novartis shall promptly
return all such tangible materials to Unigene. 
  
 Survival. Articles 2.4.1.2, 2.4.1.3, 2.4.2.2, 2.4.3 (survives the License Agreement as long as the Contract Manufacturing Agreement is in effect) 3.7, 3.8, 3.9, 3.10, 6.2.2, 6.2.3, 6.2.5, 6.2.6,8, 9, 10,11, 12.1, 12.3, 12.4, 12.6, 12.9,
12.10, 12.11, shall survive the expiration or termination of this Agreement for any reason. In addition, any other provision required to interpret and enforce the Parties’ rights and obligations under this Agreement shall also survive, but only
to the extent required for the observation and performance of the aforementioned surviving portions of this Agreement. 
  
 MISCELLANEOUS 
  
 Governing Law. This Agreement shall be deemed to have been made in the State of New Jersey, U.S.A., and its form, execution, validity, construction
and effect shall be determined in accordance with, and any dispute arising from the performance or breach hereof shall be governed by and construed in accordance with, the laws of the State of New Jersey, without reference to conflicts of laws
principles. Each of the Parties irrevocably submits to the exclusive jurisdiction of the state and federal courts situated in the State of New Jersey for purposes of any suit, action or other proceeding arising out of this Agreement or any
transaction contemplated hereby and agrees not to commence any action, suit or proceeding relating hereto except in such courts. NO PARTY HERETO SHALL CHALLENGE OR CONTEST THE 

  

 - 27 - 

 
SUBJECT MATTER OR PERSONAL JURISDICTION OF ANY SUCH COURT OR ITS VENUE OR ASSERT THE DEFENSE OF “FORUM NONCONVENIENS”. 
  
 Waiver. Neither Party may waive or release any of its rights or
interests in this Agreement except in writing. The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar
subsequent failure to perform any such term or condition. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of another condition or term.

  
 Assignment. This Agreement shall not be assignable by
either Party to any Third Party without the written consent of the other Party hereto; except either party may assign this Agreement, without such consent, to (i) an Affiliate or (ii) an entity that acquires all or substantially all of the capital
stock, business or assets of the Party to which this Agreement pertains, (whether by merger, reorganization, acquisition, sale, or otherwise) and agrees in writing to be bound by the terms and conditions of this Agreement. The terms and conditions
of this Agreement shall be binding on and inure to the benefit of the permitted successors and assigns of the Parties. 
  
 Notices. Any notices, requests and other communications hereunder shall be in writing and shall be personally delivered or sent by international
express delivery service, registered or certified air mail, return receipt requested, postage prepaid, or by facsimile (confirmed by prepaid registered or certified air mail letter or by international express delivery mail) (e.g., FedEx)), and shall
be deemed to have been properly served to the addressee upon receipt of such written communication, to the following addresses of the Parties, or such other address as may be specified in writing to the other: 
  

					
	 If to Novartis:
	  	 Novartis Pharma AG
       Lichtstrasse 35
       4002 Basel, Switzerland
       Attention: Herve Girsault
       Telephone: +41 61 324 68 77
       Telecopy: +41 61 324 23 22

		
	 with copies to:
	  	General Counsel

  
 All notices properly delivered to
Novartis as provided in this Section 12.4 shall satisfy all of Unigene’s notification obligations hereunder. 
  

					
	 If to Unigene:
	  	 Unigene Laboratories, Inc.
       110 Little Falls Road
       Fairfield, NJ 07004
       Attention: President
       Telephone: 973-882-0860
       Telecopy: 973-227-6088

  

 - 28 - 

					
	 with copies to:
	  	 Dechert LLP
       Princeton Pike Corporate Center
       P.O. Box
5218
       Princeton, New Jersey 08543-5218

		
	 	  	       For deliveries: 
       Dechert LLP
       Princeton Pike Corporate Center
       997 Lenox Drive
       Building 3, Suite 210
       Lawrenceville, New Jersey 08648

	 	  	       Attention:
       Telephone:
       Telecopy:
	  	 James Marino, Esq.
 609-620-3214
 609-620-3259

  
 Any Party may change the address to
which notices, requests, demands, claims, and other communications hereunder are to be delivered by giving the other Parties notice in the manner herein set forth. 
  
 Force Majeure. Neither Party shall be liable to the other for failure or delay in the performance of any of its
obligations under this Agreement for the time and to the extent such failure or delay is caused by earthquake, riot, civil commotion, terrorism, war, hostilities between nations, governmental law, order or regulation, embargo, action by the
government or any agency thereof, act of God, storm, fire, accident, labor dispute or strike, sabotage, explosion or other similar or different contingencies, in each case, beyond the reasonable control of the respective Party. The Party affected by
force majeure shall provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities), and will use its commercially
reasonable efforts to overcome the difficulties created thereby and to resume performance of its obligations as soon as practicable. If the performance of any obligation under this Agreement is delayed owing to a force majeure for any continuous
period of more than six (6) months, the Parties hereto shall consult with respect to an equitable solution including, without limitation, the possible termination of this Agreement. 
  
 Independent Contractors. Nothing contained in this Agreement is intended implicitly, or is to be construed, to
constitute Novartis or Unigene as partners or joint venturers in the legal sense. No Party hereto shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of any other Party or to bind any
other Party to any contract, agreement or undertaking with any Third Party. 
  
 Other Obligations. Except as expressly provided in this Agreement or as separately agreed upon in writing between Unigene and Novartis, each Party shall bear its own costs incurred in connection with the
implementation of the obligations under this Agreement. 
  

 - 29 - 

 Severability. If any of the terms or provisions of this Agreement are in conflict with any
applicable statute or rule of law, then such terms or provisions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed to be modified to conform with such statute or rule of law. In the event that the terms
and conditions of this Agreement are materially altered as a result of the above, the Parties will renegotiate the terms and conditions of this Agreement to resolve any inequities. 
  
 Further Assurances. At any time or from time to time on and after the date of this Agreement, either Party shall at
the request of the other Party (i) deliver to the requesting Party such records, data or other documents consistent with the provisions of this Agreement, (ii) execute, and deliver or cause to be delivered, all such consents, documents or further
instruments of assignment, transfer or license, and (iii) take or cause to be taken all such actions, as the requesting Party may reasonably deem necessary or desirable in order for the requesting Party to obtain the full benefits of this Agreement
and the transactions contemplated hereby. 
  
 Entire Agreement,
Waivers, Etc. This Agreement, including all its Exhibits, together with the Confidentiality Agreement constitutes the entire agreement, both written or oral, with respect to the subject matter hereof, and supersedes and terminates all prior or
contemporaneous understandings or agreements, whether written or oral, between the Parties with respect to such subject matter hereof. In the event of any conflicts among the Agreements, this Agreement shall govern. No terms or provisions of this
Agreement shall be varied or modified by any prior or subsequent statement, conduct or act of either of the Parties, except that the Parties may amend this Agreement by written instruments specifically referring to and executed in the same manner as
this Agreement. 
  
 Headings, Construction and
Interpretations. The headings used in this Agreement have been inserted for convenience of reference only and do not define or limit the provisions hereof. The Parties have participated jointly in the negotiation and drafting of this Agreement.
In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the
authorship of any of the provisions of this Agreement. Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation”.
The words “hereof”, “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. All terms defined in
this Agreement shall have the defined meanings when used in any certificate or other document made or delivered pursuant hereto unless otherwise defined therein. The definitions contained in this Agreement are applicable to the singular as well as
the plural forms of such terms and to the masculine as well as to the feminine and neuter genders of such term. 
  

 - 30 - 

 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be
deemed an original and all of which together shall constitute one and the same instrument even if both Parties have not executed the same counterpart. 
  

 -31- 

 IN WITNESS WHEREOF, the Parties hereto have caused this License Agreement to be duly executed by their authorized
representatives as of the Effective Date. 
  

									
	 UNIGENE LABORATORIES, INC.
	 	 	 	 NOVARTIS PHARMA AG

					
	By:	 	/S/    WARREN P.
LEVY        	 	 	 	By:	 	/S/    HERVE
GIRSAULT        
	Name:	 	Warren P. Levy	 	 	 	Name:	 	Herve Girsault
					
	Title:	 	President and Chief Executive Officer	 	 	 	Title:	 	Head, Global Partnering
					
	Date:	 	 4/7/04
	 	 	 	Date:	 	 4/7/04

					
	 	 	 	 	 	 	By:	 	/S/    BETTINA
EGLI        
	 	 	 	 	 	 	Name:	 	Bettina Egli
					
	 	 	 	 	 	 	Title:	 	Legal Counsel
					
	 	 	 	 	 	 	Date:	 	 4/7/04

  

 -32- 

 EXHIBIT A 
  

CLINICAL SUPPLY AGREEMENT 
  
 THIS CLINICAL SUPPLY AGREEMENT (this “Agreement”) is entered into as of April 7th, 2004 (the “Effective Date”), by and between Novartis Pharma AG, a Swiss corporation (“Novartis”), and Unigene Laboratories, Inc., a
Delaware corporation (“Unigene”) (each a “Party” and collectively, the “Parties”). All terms not otherwise defined herein shall have their respective meaning as set forth in the License Agreement and the Contract
Manufacturing Agreement (as defined below). 
  

	1.	GENERAL SCOPE OF AGREEMENT 

  
 In connection with that certain License Agreement, dated as of the date hereof, by and between Novartis and Unigene (the “License
Agreement”), and that certain Contract Manufacturing Agreement between ** GmbH and Unigene, Unigene hereby agrees to manufacture, sell and deliver to Novartis the quantities of material described in the Task Order attached hereto as Exhibit A
(the “Product”), and in conformity with the terms of the Task Order and the Quality Assurance Agreement entered into by Unigene and Novartis as of the date hereof attached hereto as Exhibit B (the Task Order and the Quality Assurance
Agreement are referred to collectively herein as the “Quality Requirements”). 
  

	2.	TERM OF AGREEMENT 

  
 Unless sooner terminated pursuant to Paragraph 12, this Agreement shall commence on the date set forth above and shall continue in force until the Termination Date as
defined herein. The Termination Date shall be the date on which Novartis accepts the final shipment of Product to be delivered pursuant to Paragraph 3C of this Agreement. 
  

	3.	ACCEPTANCE AND PAYMENT 

  

	 	A.	Acceptance 

  

	 	(1)	Product delivered pursuant to this Agreement shall be subject to inspection at Novartis’ facilities for compliance with the Quality Requirements. 

  

	 	(2)	Within forty-five (45) days after the applicable shipment of the Product is received by Novartis at the specified Novartis location, and Unigene has provided the documentation
required by the Task Order, Novartis may analyze the shipment of the Product If Novartis determines that any shipment of Product, in whole or in part, fails to conform to the Quality Requirements, Novartis shall so inform Unigene in writing
describing the reason for such rejection in detail and providing copies of all written materials upon which such rejection is based. 

  

	 	B.	Consequences of Rejection 

  
 If Unigene receives a complaint under Paragraph 3(A), the following procedures shall apply: 
  

 A-1 

	 	(a)	If the alleged defect concerns the quantity or quality of the API delivered and Unigene accepts the details submitted by Novartis as to the API’s noncompliance, Unigene shall
supply to Novartis (at Unigene’s cost, including the cost of raw materials and components related thereto) the replacement quantity of the API that was allegedly missing or defective from the original batch. 

  

	 	(b)	If the alleged defect concerns the quantity or quality of the API delivered and Unigene does not accept the details submitted by Novartis, then within thirty (30) days from the date
on which the details of Novartis’ complaint are received by Unigene, Unigene will appoint an independent scientific and technical expert acceptable to Novartis to review Novartis’ details supporting its complaint of noncompliance. Novartis
shall not unreasonably refuse to accept the appointment of the independent scientific and technical expert identified by Unigene. The findings of the expert shall be final and conclusively binding on the parties as to whether the API complies with
the Quality Requirements. If the analysis of the expert does not confirm Novartis’ complaint, Novartis shall pay for any replacement quantities delivered by Unigene. If the expert holds that the API does not meet the Quality Requirements, all
the fees and costs of the expert and the independent laboratory appointed by the expert to analyze the API shall be paid by Unigene, and Novartis shall have no obligation to pay for such replacement quantities of API and Unigene shall be responsible
for all costs associated therewith (including the cost of raw materials, components and shipment related thereto). If the expert rejects Novartis’ complaint, all such fees and costs of the laboratory and the expert will be paid by Novartis,
Novartis shall pay for any replacement quantities delivered by Unigene in addition to the original quantities delivered, and Novartis shall be considered to have finally and completely accepted such batch of the API. 

  

	 	C.	Except as otherwise provided in Paragraph 3B(b), Novartis shall pay for Product accepted by it within forty-five (45) days after receipt by Novartis of an invoice from Unigene
unless in dispute. All sums due to Unigene shall be payable in United States Dollars by bank wire transfer in immediately available funds to such bank account as Unigene shall designate. The Product will be shipped, at Novartis’ cost, from
Unigene FCA Boonton, New Jersey INCOTERMS 2000 in accordance with Novartis’ shipping instructions as provided in writing to Unigene. In addition, Unigene shall use Novartis’ designated carrier and shall ship the Product to the address
designated on the Task Order. Risk of loss in transit from Novartis’ designated carrier shall lie with Novartis. Unigene shall cooperate with Novartis’ designated carrier and provide all required carrier documentation for the shipment of
Product. Novartis shall be responsible only for those taxes imposed on a purchaser by operation of law. 

  

	 	D.	 Novartis has the right to purchase from Unigene a total of ** of Product (the “Total Amount”) by ** (the “Obligated Date”) at a price of U.S. **
per ** (the “Obligated Price”). The Total Amount comprises the sum of the “Obligated Amount” (** of Product) and the “Additional Amount” (** of Product). Upon the Effective Date, Novartis shall pay to Unigene a
non-refundable payment of U.S. $2,100,000 for the order of the Product equal to the sum of (i) U.S. **, and (ii) U.S. ** The total of two million one hundred thousand dollars (U.S. $2,100,000) shall be paid by Novartis to Unigene within ** days of
the Effective Date. The payment in Paragraph 3D(i) is 

  

 A-2 

	 	 
payment in full for the Obligated Amount to be delivered in accordance with the Task Order. The payment in Paragraph 3D(ii) is the down payment for the
Additional Amount to be delivered in accordance with the Task Order. Novartis shall inform Unigene in writing on or before ** whether it wishes Unigene to prepare and deliver the Additional Amount in accordance with the Task Order. Unigene shall
credit the U.S.** down payment in Paragraph 3D(ii) at $U.S. ** of Product on a ** for each shipment invoiced to Novartis of Product which is part of the Additional Amount, and Novartis shall pay the remainder of U.S.** of Additional Amount. For
example, if Unigene ships ** of Additional Product, the aggregate purchase price will be ** of which will be credited against the down payment (paid in accordance with Paragraph 3D (ii) and ** which will be due in accordance with Paragraph 3C. If
after Novartis has provided notice on or before ** that it wishes to purchase the Additional Amount, Novartis fails to purchase all or part of the Additional Amount by the Obligated Date, then Novartis shall pay Unigene the difference between (i)
the Additional Amount multiplied by the Obligated Price, and (ii) the amount actually paid to Unigene by Novartis for the portion of Additional Amount purchased pursuant to this Agreement. 

  

	 	E.	Novartis may employ Product supplied by Unigene under this Agreement in connection with ** clinical trials. 

  

	4.	COMMUNICATIONS 

  
 In the Task Order, the Parties shall identify individuals who shall serve as the Parties’ representatives as to technical and administrative matters. Except in case
of emergency, all communications between Novartis and Unigene shall be made through these representatives. Any written communication required or deemed necessary hereunder shall be deemed to have been properly served or sent if delivered in person,
sent by a recognized overnight delivery service, or deposited in the United States mail, postage prepaid, for mailing by registered or certified mail, and addressed to these representatives. Unigene shall immediately inform Novartis of any
occurrence that creates material uncertainty as to Unigene’s ability to comply fully with any aspect of the Task Order. Without limiting Unigene’s obligations pursuant to this Paragraph, the Parties’ technical representatives shall
establish a regular schedule of conferences to facilitate such communications. 
  

	5.	INTELLECTUAL PROPERTY 

  
 Intellectual property matter shall be governed by Article 6 of the License Agreement. 
  

	6.	CONFIDENTIALITY AND EXCHANGE OF INFORMATION 

  
 Confidentiality and the Exchange of Confidential Information shall be governed by Article 8
of the License Agreement. 
  

	7.	PUBLICITY 

  
 Except as otherwise permitted by Section 8.3 of the License Agreement, neither Party shall disclose either the fact or terms of this Agreement without the prior written
consent of the other Party except as required by law. 
  
 Neither Party will use,
or authorize others to use, the name, symbols, or marks of the other 

  

 A-3 

 
Party in any advertising or publicity material or make any form of representation or statement with regard to this Agreement or any Task Order issued
hereunder which would constitute an express or implied endorsement by the other Party of any commercial product or service without that other Party’s prior written approval. 
  

	8.	DOCUMENTATION, INSPECTIONS AND AUDITING 

  
 Unigene will document all aspects of its procedures as described in the Task Order and
Quality Assurance Agreement and will deliver to Novartis (or, where applicable, make available to Novartis for inspection during mutually agreeable times during normal business hours) in a timely manner all of the documentation described in the Task
Order. In addition, to the extent that such requests do not include Unigene proprietary or trade secret information and do not conflict with other contractual or legal obligations of Unigene, Unigene will cooperate in good faith to provide any
additional documentation that Novartis may reasonably require to determine whether to accept or reject the Product. If Unigene declines to provide any additional documentation in its possession and requested by Novartis, then Novartis may, in its
sole discretion, reject the Product. During the term of this Agreement and for three (3) years thereafter (or for such longer period as may be required by law, regulation, or other administrative requirement), Unigene will maintain all books,
records and other documents (including but not limited to the documents referred to in Paragraph 8A) relating to the performance of this Agreement or required to be kept by law or permit. 
  

	9.	INDEMNIFICATION 

  

	 	A.	Unigene agrees to indemnify, defend and hold Novartis and its subsidiaries and affiliates (including all officers, directors, employees, contractors and agents of the foregoing)
harmless from and against any and all third party claims, demands, causes of action, damages, liabilities, losses, costs and expenses, including attorneys’ fees (collectively, the “Claims”), arising out of the negligence or willful
misconduct of Unigene in the performance of obligations under this Agreement (including, but not limited to, the performance of Unigene’s employees, subcontractors or agents); or from the breach by Unigene of its warranties, except to the
extent that such Claims were caused by the negligence or willful misconduct of Novartis. Unigene further agrees to indemnify, defend and hold Novartis and its subsidiaries and affiliates (including all officers, directors, employees, contractors and
agents of the foregoing) harmless from and against any and all Claims arising out of the actual or alleged infringements of any patents, trademarks, copyrights or other third party intellectual property rights arising from the manufacture of the
Product by Unigene.**. 

  

	 	B.	 Novartis agrees to indemnify, defend and hold Unigene and its subsidiaries and affiliates (including all officers, directors, employees, contractors and agents of
the foregoing) harmless from and against any and all Claims, arising out of the negligence or willful misconduct of Novartis in the performance of its obligations under this Agreement (including, but not limited to, the performance of Novartis’
employees, subcontractors or agents); or from the administration or use of the Product by Novartis, except to the extent that such Claims were caused by the negligence or willful misconduct of Unigene in the performance of its obligations 

  

 A-4 

	 	 
under this Agreement (including, but not limited to, the performance of Unigene’s employees, subcontractors or agents); or from the breach by Unigene of
its warranties. 

  

	 	C.	The Party seeking indemnification (“Indemnitee”) will notify promptly the Party from which indemnification is sought (“Indemnitor”) of any complaint, claim or
injury relating to any loss subject to indemnification hereunder. Indemnitor shall have the right to select defense counsel and to direct and control the defense or settlement of any such liability, claim, action or suit. Indemnitee shall cooperate
fully with Indemnitor and its legal representatives in the investigation and defense relating to any loss subject to indemnification hereunder. 

  

	 	D.	EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, UNIGENE MAKES NO WARRANTIES AS TO THE PRODUCT, AND SPECIFICALLY DISCLAIMS ANY IMPLIED WARRANTIES, INCLUDING AS TO THE MERCHANTABILITY
OF THE PRODUCT OR ITS FITNESS FOR A PARTICULAR PURPOSE OR THAT THE USE OF THE PRODUCT WILL NOT INFRINGE ANY PATENT OR PROPRIETARY RIGHTS HELD BY A THIRD PARTY. 

  

	10.	INSURANCE 

  

	 	A.	Unigene agrees that it shall maintain liability insurance in the amount of ** for a period of five (5) years following termination of this Agreement. 

  

	 	B.	Upon execution of this Agreement, Unigene will provide Novartis with evidence of Unigene’s insurance. Unigene will name Novartis as an additional insured party under
Unigene’s insurance policy. Unigene will not change or cancel Unigene’s insurance program and will make all premium payments needed to keep such insurance in force. In the event that Unigene becomes aware of any changes to its insurance
program, Unigene will promptly notify Novartis in writing of such changes. 

  

	11.	FORCE MAJEURE 

  
 Neither Party shall be liable to the other for any failure to deliver or receive Product or for any delay in delivery or receipt of Product when such failure or delay
shall be caused (directly or indirectly) by fire; flood; accident; explosion; equipment or machinery breakdown; sabotage; strike or any labor disturbance (regardless of the reasonableness of the demands of labor); civil commotion; riot; invasion;
war; act of terrorism; any act, restraint, requisition, regulation or direction of any governmental authority (whether or not valid); shortage of labor, fuel, power or raw materials; inability to obtain supplies; inability to obtain or delays of
transportation facilities; any Act of God; or any other event beyond the reasonable control of the Party whose performance is affected (each, an “Event of Force Majeure”). The Party whose performance is so affected shall provide prompt
written notice to the other, shall indicate the estimated duration of such Event of Force Majeure, and shall use all commercially reasonable efforts to mitigate the effects of such Event of Force Majeure. 

  

 A-5 

 
If, by reason of any such Event of Force Majeure, Unigene is excused from performance, then, to the extent Product are not delivered to Novartis in the
quantities or at the times required hereunder, Novartis may purchase a replacement product from other sources without liability or obligation to Unigene. In the event Novartis purchases a replacement product from another source, then Novartis may,
to the full extent of such purchases, reduce its quantity purchase commitment, if any, hereunder. All such quantities of replacement product so purchased by Novartis shall be considered Product purchased from Unigene for purposes of calculating
discounts based on volume allowed under this Agreement, if any. During any period of shortage due to any of said Events of Force Majeure, Unigene shall allocate its supply of Product fairly and equitably among its customers, including Novartis. In
addition, Novartis may, at its option, extend the Term of this Agreement to permit partial or total delivery of Product not delivered because of any such Event of Force Majeure. If such Event of Force Majeure continues for more than sixty (60) days,
Novartis has the option, at any time thereafter during which the Event of Force Majeure is continuing, to terminate this Agreement without liability to Unigene, except to pay for Product already accepted. 
  

	12.	TERMINATION 

  

	 	A.	This Agreement and the Task Order issued hereunder may be terminated by Novartis with or without cause upon thirty (30) days written notice to Unigene; provided, however, that, if
Novartis terminates this Agreement without cause, together with the delivery of such written notice, Novartis shall deliver to Unigene a termination payment**; provided further, however, that if Novartis terminates this Agreement with cause, within
thirty (30) days after such written notice, Novartis shall deliver to Unigene a termination payment for costs incurred by Unigene for any fulfillment of Unigene’s obligations under this Agreement through the date of such written notice, . Upon
receipt of such written notice, Unigene shall cease all activities under this Agreement related to the manufacture and delivery of the Product, except as to the delivery of Product already accepted and paid for. 

  

	 	B.	In the event that (a) either Party becomes insolvent or is unable to pay its debts as they become due, or a petition in bankruptcy or for reorganization is filed by or against them,
or a receiver is appointed of the whole or any substantial portion of its property; or (b) either Party is in material breach of its obligations hereunder, which breach remains uncured for sixty (60) business days following receipt of written notice
from the other specifying the breach, then the other Party shall have the right to terminate this Agreement with immediate effect, and without prejudice to its other rights or remedies, by written notice of such election. 

 

	 	C.	 This Agreement and the Task Order may be terminated by either party for a material breach upon sixty (60) days prior written notice, during which period the other
party shall have the opportunity to cure such breach. Notwithstanding the above, in the case of a failure of Novartis to pay any payment due hereunder, the period for cure of any such failure to pay following written notice from Unigene thereof
shall be thirty (30) days and, unless payment is made by Novartis within such period or unless Novartis has notified Unigene that a good faith dispute exists regarding Novartis’ 

  

 A-6 

	 	 
failure to pay, the termination shall become effective at the end of such thirty (30) day period. 

  

	13.	CONFORMANCE WITH LAW AND ACCEPTED PRACTICE; WARRANTIES

  

	 	A.	Unigene shall perform this Agreement: (i) in a professional manner; and (ii) in conformance with that level of care and skill ordinarily exercised in similar circumstances by other
manufacturers of products that are the same as or similar to the Product. Unigene warrants that all Product furnished hereunder has been manufactured, prepared for shipment and delivered to Novartis’ commercial carrier in accordance with all
applicable federal, state and local laws, rules, regulations, orders, ordinances and guidelines and good industry practice. Unigene has and will maintain all licenses, permits, and similar authorizations required for the manufacturing, processing
and packaging of the Product. 

  

	 	B.	Unigene warrants that all Product supplied hereunder: (i) is owned by Unigene free of any lien, claim or encumbrance; (ii) conforms fully to every specification set forth in the
Task Order; (iii) conforms fully to every specification set forth in the Quality Assurance Agreement; (iv) to Unigene’s knowledge and belief, is free from contamination and any latent or patent defects in design, materials or workmanship; (v)
does not, to Unigene’s knowledge and belief, infringe any patent, any other intellectual property right or any other proprietary right of any third party for which Unigene does not have a license; and (vi) is, to Unigene’s knowledge and
belief, suitable for use in humans; (vii) **; (viii) **. Without limiting the generality of the foregoing, Unigene acknowledges and understands that Novartis may use the Product, in Novartis’ sole discretion, as the active pharmaceutical
ingredient in clinical (human) trials, and Novartis acknowledges and understands that Unigene: (1) has not received any governmental approval in the United States for the use of the Product in humans; and (2) has no knowledge of any further
formulation of the Product by Novartis, nor of the protocol that Novartis may utilize for human administration of the Product. 

  

	14.	SUBCONTRACTORS 

  
 Unigene shall not subcontract any of this Agreement without the prior written approval of Novartis. Any such approval shall not relieve Unigene of its obligations under
this Agreement. 
  

	15.	APPLICABLE LAW 

  
 This Agreement shall be construed by and enforced in accordance with the laws of the State of New Jersey without regard to principles of conflicts of laws. Any lawsuit
which may arise with respect to this Agreement shall be brought only in a court of competent jurisdiction located in the State of New Jersey. 
  

 A-7 

	16.	INDEPENDENT CONTRACTOR 

  

	 	A.	In the performance of this Agreement, Unigene shall be deemed to be and shall be an independent contractor and, as such, neither the Unigene nor its employees shall be entitled to
any benefits applicable to employees of Novartis. 

  

	 	B.	Neither Party is authorized or empowered to act as agent for the other for any purpose and shall not on behalf of the other enter into any contract, warranty or representation as to
any matter. Neither Party shall be bound by the acts or conduct of the other. 

  

	17.	ENTIRE AGREEMENT 

  
 This Agreement, together with the Task Order (annexed hereto as Exhibit A), the Quality Assurance Agreement (annexed hereto as Exhibit B), the License Agreement including
all its Exhibits represent the entire understanding between the Parties with respect to the subject matter hereof and merge and supercede all prior and contemporaneous agreements or understandings, oral or written with respect thereto. None of the
Agreements referenced in this Paragraph shall be modified except by a writing signed by the Parties to the particular Agreement to be modified specifying that it is a modification to the particular Agreement to be modified 
  

	18.	SEVERABILITY 

  
 The invalidity or unenforceability of any term or provision of this Agreement shall not affect the validity or enforceability of any other term or provision hereof.

  

	19.	ASSIGNMENT 

  
 This Agreement shall not be assignable by either Party to any third party without the written consent of the other Party hereto; provided, however, that either party may
assign this Agreement, without such consent, to (i) an affiliate; or (ii) an entity that acquires all or substantially all of the capital stock, business or assets of Unigene to which this Agreement pertains, (whether by merger, reorganization,
acquisition, sale, or otherwise) and agrees in writing to be bound by the terms and conditions of this Agreement. The terms and conditions of this Agreement shall be binding on and inure to the benefit of the permitted successors and assigns of the
Parties. 
  

	20.	WAIVER 

  
 The failure of a Party to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver or deprive that Party of the right to insist upon strict adherence to that term or
any other term of this Agreement. Any waiver must be in writing and signed by the Party making the waiver. 
  

	21.	DEBARMENT CERTIFICATION 

  
 Unigene hereby represents and warrants that neither Unigene nor any person employed by Unigene in connection with any work to be performed for or on behalf of Novartis
has been debarred under Section 306(a) or (b) of the Federal Food, Drug and Cosmetic Act, and that no debarred person will in the future be employed by the Unigene in connection with any work to be performed for or on behalf of Novartis. If at any
time after execution of this Agreement, the Unigene becomes aware that the Unigene or any person employed by the Unigene in connection with any work to be performed for or on behalf of Novartis shall become or shall be in the process of being
debarred, the Unigene hereby agrees to so notify Novartis at once. 
  

 A-8 

	22.	SURVIVAL 

  
 The provisions of Paragraphs 5, 6, 7, 8B, 9, 10, 15, 18, 19 and 20 and this Paragraph 22 shall survive the expiration or termination of this Agreement as well as all
payment obligations pending at the time of expiration or termination, if any. 
  

 A-9 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their respective duly
authorized representatives as of the day and year first above written. 
  

			
	 NOVARTIS PHARMA AG

	
	 /S/    HERVE
GIRSAULT        

	Name:	 	Herve Girsault
	Title:	 	Head, Global Partnering

  

			
	
	/S/    BETTINA
EGLI        
	Name:	 	Bettina Egli
	Title:	 	Legal Counsel

  

			
	UNIGENE LABORATORIES, INC.
	
	/S/    WARREN P.
LEVY        
	 	 	Warren P. Levy
	 	 	President and Chief Executive Officer

  

 A-10 

 EXHIBIT A 
 TASK ORDER 
  

	1.	Product: recombinant calcitonin ** 

  

	2.	Quantity of Product: a total of **, to be supplied as follows: 

  

	 	**	(Obligated Amount) 

  

	 	**	(Obligated Amount) 

  

	 	**	(Obligated Amount) 

  

	 	**	(Additional Amount) 

  

	 	**	(Additional Amount) 

  

	 	**	(Additional Amount) 

  

	3.	To be delivered to: 

  
 Robert Gallagher 
  
 One Health Plaza 
  
 East Hanover, NJ 07936 
  

	4.	Product Specifications: as attached hereto in Schedule 1 

  

	5.	Price: ** 

  

	6.	Supplier Procedure Documentation: 

  
 Unigene will provide the following documents and/or information to Novartis, it being understood that any and all data to be provided in accordance with
this Task Order shall be in compliance with Section 2.2.4 (Right of Reference) of the License Agreement: 
  

	 	A.	** 

  

	 	B.	** 

  

	 	C.	** 

  

	 	D.	** 

  

	 	E.	** 

  

	 	F.	** 

  

	 	G.	** 

  

 A - 1 

	 	H.	** 

  

	 	I.	** 

  

	 	J.	** 

  

	 	K.	** 

  

	 	L.	** 

  

	 	M.	** 

  

	 	N.	** 

  

	 	O.	** 

  

	7.	Contacts: 

  

			
	If to Novartis for Technical Matters:	  	If to Supplier for Technical Matters:
		
	Simon Bateman, Ph.D/	  	Paul Shields, Ph.D.
		
	Director, Technical Research and Development	  	Director, Plant Operations
		
	Novartis Pharmaceuticals Corporation	  	Unigene Laboratories, Inc.
		
	One Health Plaza	  	83 Fulton St.
		
	East Hanover, New Jersey 07936	  	Boonton, New Jersey 07005
		
	If to Novartis for Administrative Matters:	  	If to Supplier for Administrative Matters:
		
	Robert Wager	  	James P. Gilligan, Ph.D, MSIB
		
	 	  	Vice President of Product Development
		
	Novartis Pharmaceuticals Corporation	  	Unigene Laboratories, Inc.
		
	One Health Plaza	  	110 Little Falls Road
		
	East Hanover, New Jersey 07936	  	Fairfield, New Jersey 07004

  

 A - 2 

 SCHEDULE 1 
 PRODUCT SPECIFICATIONS 
  
 **

  

 EXHIBIT B 
  

CONTRACT MANUFACTURING AGREEMENT 
  

 EXHIBIT C ** 
  
 ** 
  

 EXHIBIT D 
  

UNIGENE SOLE IMPROVEMENTS 
  
 CONFIDENTIAL 
  

							
	 1)
	 	 	 	**	 	**
				
	 2)
	 	 	 	**	 	**
				
	 3)
	 	 	 	**	 	**

  

 EXHIBIT E 
  

** 
  
  

																			
	 Invention

	  	Country

	 	 	Status

	 	 	 Application/
 Patent #

	 	 	 Application/
 Issued

	 	 	Expiration date

	 	 	Number of
Patents

	 
	 **
	  	 	 	 	*	*	 	*	*	 	*	*	 	*	*	 	*	*
	 	  	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	

	 **
	  	*	*	 	*	*	 	*	*	 	*	*	 	*	*	 	*	*
	 **
	  	*	*	 	*	*	 	*	*	 	*	*	 	*	*	 	*	*

  

 EXHIBIT F 
  

PRODUCT SUPPLY AGREEMENT 
  

 EXHIBIT G 
  

PATENT SECURITY AGREEMENTS 
  

 EXHIBIT H 
  

UNIGENE PRESS RELEASEExhibit 4.1

                              GEORGIA POWER COMPANY

                                       TO

                              JPMORGAN CHASE BANK,
                                     TRUSTEE

                      TWENTY-SECOND SUPPLEMENTAL INDENTURE

                           DATED AS OF AUGUST 20, 2004

                           SERIES V 4.10% SENIOR NOTES

                               DUE AUGUST 15, 2009

<PAGE>

TABLE OF CONTENTS1

                                                                    PAGE

ARTICLE 1.............................................................1

SECTION 101.               Establishment..............................1
                           -------------

SECTION 102.               Definitions................................2
                           -----------

SECTION 103.               Payment of Principal and Interest..........2
                           ---------------------------------

SECTION 104.               Denominations..............................3
                           -------------

SECTION 105.               Global Securities..........................3
                           -----------------

SECTION 106.               Transfer...................................4
                           --------

ARTICLE 2.............................................................4

SECTION 201.               Recitals by Company........................4
                           -------------------

SECTION 202.               Ratification and Incorporation of
                           ----------------------------------
                           Original Indenture.........................4
                           ------------------

SECTION 203.               Executed in Counterparts...................4
                           ------------------------

1This Table of Contents does not constitute part of the Indenture or have any
bearing upon the interpretation of any of its terms and provisions.

<PAGE>

           THIS TWENTY-SECOND SUPPLEMENTAL INDENTURE is made as of the 20th day
of August, 2004, by and between GEORGIA POWER COMPANY, a Georgia corporation,
241 Ralph McGill Boulevard, N.E., Atlanta, Georgia 30308-3374 (the "Company"),
and JPMORGAN CHASE BANK, a New York banking corporation, 4 New York Plaza, New
York, New York 10004 (the "Trustee").

                              W I T N E S S E T H:

           WHEREAS, the Company has heretofore entered into a Senior Note
Indenture, dated as of January 1, 1998 (the "Original Indenture"), with JPMorgan
Chase Bank (formerly known as The Chase Manhattan Bank), as heretofore
supplemented;

           WHEREAS, the Original Indenture is incorporated herein by this
reference and the Original Indenture, as heretofore supplemented and as further
supplemented by this Twenty-Second Supplemental Indenture, is herein called the
"Indenture";

           WHEREAS, under the Original Indenture, a new series of Senior Notes
may at any time be established by the Board of Directors of the Company in
accordance with the provisions of the Original Indenture and the terms of such
series may be described by a supplemental indenture executed by the Company and
the Trustee;

           WHEREAS, the Company proposes to create under the Indenture a new
series of Senior Notes;

           WHEREAS, additional Senior Notes of other series hereafter
established, except as may be limited in the Original Indenture as at the time
supplemented and modified, may be issued from time to time pursuant to the
Indenture as at the time supplemented and modified; and

           WHEREAS, all conditions necessary to authorize the execution and
delivery of this Twenty-Second Supplemental Indenture and to make it a valid and
binding obligation of the Company have been done or performed.

           NOW, THEREFORE, in consideration of the agreements and obligations
set forth herein and for other good and valuable consideration, the sufficiency
of which is hereby acknowledged, the parties hereto hereby agree as follows:

                                    ARTICLE 1

                              Series V Senior Notes

           SECTION 101. Establishment. There is hereby established a new series
of Senior Notes to be issued under the Indenture, to be designated as the
Company's Series V 4.10% Senior Notes due August 15, 2009 (the "Series V
Notes").

           There are to be authenticated and delivered $125,000,000 principal
amount of Series V Notes, and such principal amount of the Series V Notes may be
increased from time to time pursuant to Section 301 of the Original Indenture.
All Series V Notes need not be issued at the same time and such series may be
reopened at any time, without the consent of any Holder, for issuances of
additional Series V Notes. Any such additional Series V Notes will have the same
interest rate, maturity and other terms as those initially issued. No Series V
Notes shall be authenticated and delivered in excess of the principal amount as
so increased except as provided by Sections 203, 303, 304 or 907 of the Original
Indenture. The Series V Notes shall be issued in definitive fully registered
form.

           The Series V Notes shall be issued in the form of one or more Global
Securities in substantially the form set out in Exhibit A hereto. The Depositary
with respect to the Series V Notes shall be The Depository Trust Company.

           The form of the Trustee's Certificate of Authentication for the
Series V Notes shall be in substantially the form set forth in Exhibit B hereto.

           Each Series V Note shall be dated the date of authentication thereof
and shall bear interest from the date of original issuance thereof or from the
most recent Interest Payment Date to which interest has been paid or duly
provided for. The Series V Notes will not be redeemable at the option of the
Company prior to the Stated Maturity and will not have a sinking fund.

           SECTION 102. Definitions. The following defined terms used herein
shall, unless the context otherwise requires, have the meanings specified below.
Capitalized terms used herein for which no definition is provided herein shall
have the meanings set forth in the Original Indenture.

           "Interest Payment Dates" means February 15 and August 15 of each
year, commencing on February 15, 2005.

           "Original Issue Date" means August 20, 2004.

           "Regular Record Date" means, with respect to each Interest Payment
Date, the close of business on the 15th calendar day preceding such Interest
Payment Date (whether or not a Business Day).

           "Stated Maturity" means August 15, 2009.

           SECTION 103. Payment of Principal and Interest. The principal of the
Series V Notes shall be due at Stated Maturity. The unpaid principal amount of
the Series V Notes shall bear interest at the rate of 4.10% per annum until paid
or duly provided for. Interest shall be paid semiannually in arrears on each
Interest Payment Date to the Person in whose name the Series V Notes are
registered on the Regular Record Date for such Interest Payment Date, provided
that interest payable at the Stated Maturity of principal will be paid to the
Person to whom principal is payable. Any such interest that is not so punctually
paid or duly provided for will forthwith cease to be payable to the Holders on
such Regular Record Date and may either be paid to the Person or Persons in
whose name the Series V Notes are registered at the close of business on a
Special Record Date for the payment of such defaulted interest to be fixed by
the Trustee, notice whereof shall be given to Holders of the Series V Notes not
less than ten (10) days prior to such Special Record Date, or be paid at any
time in any other lawful manner not inconsistent with the requirements of any
securities exchange, if any, on which the Series V Notes shall be listed, and
upon such notice as may be required by any such exchange, all as more fully
provided in the Original Indenture.

           Payments of interest on the Series V Notes will include interest
accrued to but excluding the respective Interest Payment Dates. Interest
payments for the Series V Notes shall be computed and paid on the basis of a
360-day year of twelve 30-day months. In the event that any date on which
interest is payable on the Series V Notes is not a Business Day, then a payment
of the interest payable on such date will be made on the next succeeding day
that is a Business Day (and without any interest or other payment in respect of
any such delay), with the same force and effect as if made on the date the
payment was originally payable.

           Payment of the principal and interest due at the Stated Maturity of
the Series V Notes shall be made upon surrender of the Series V Notes at the
Corporate Trust Office of the Trustee. The principal of and interest on the
Series V Notes shall be paid in such coin or currency of the United States of
America as at the time of payment is legal tender for payment of public and
private debts. Payments of interest (including interest on any Interest Payment
Date) will be made, subject to such surrender where applicable, at the option of
the Company, (i) by check mailed to the address of the Person entitled thereto
as such address shall appear in the Security Register or (ii) by wire transfer
or other electronic transfer at such place and to such account at a banking
institution in the United States as may be designated in writing to the Trustee
at least sixteen (16) days prior to the date for payment by the Person entitled
thereto.

           SECTION 104. Denominations. The Series V Notes may be issued in
denominations of $1,000, or any integral multiple thereof.

           SECTION 105. Global Securities. The Series V Notes will be issued in
the form of one or more Global Securities registered in the name of the
Depositary (which shall be The Depository Trust Company) or its nominee. Except
under the limited circumstances described below, Series V Notes represented by
one or more Global Securities will not be exchangeable for, and will not
otherwise be issuable as, Series V Notes in definitive form. The Global
Securities described above may not be transferred except by the Depositary to a
nominee of the Depositary or by a nominee of the Depositary to the Depositary or
another nominee of the Depositary or to a successor Depositary or its nominee.

           Owners of beneficial interests in such a Global Security will not be
considered the Holders thereof for any purpose under the Indenture, and no
Global Security representing a Series V Note shall be exchangeable, except for
another Global Security of like denomination and tenor to be registered in the
name of the Depositary or its nominee or to a successor Depositary or its
nominee. The rights of Holders of such Global Security shall be exercised only
through the Depositary.

           Subject to the procedures of the Depositary, a Global Security shall
be exchangeable for Series V Notes registered in the names of persons other than
the Depositary or its nominee only if (i) the Depositary notifies the Company
that it is unwilling or unable to continue as a Depositary for such Global
Security and no successor Depositary shall have been appointed by the Company,
or if at any time the Depositary ceases to be a clearing agency registered under
the Securities Exchange Act of 1934, as amended, at a time when the Depositary
is required to be so registered to act as such Depositary and no successor
Depositary shall have been appointed by the Company, in each case within 90 days
after the Company receives such notice or becomes aware of such cessation, (ii)
the Company in its sole discretion determines that such Global Security shall be
so exchangeable, or (iii) there shall have occurred an Event of Default with
respect to the Series V Notes. Any Global Security that is exchangeable pursuant
to the preceding sentence shall be exchangeable for Series V Notes registered in
such names as the Depositary shall direct.

           SECTION 106. Transfer. No service charge will be made for any
transfer or exchange of Series V Notes, but payment will be required of a sum
sufficient to cover any tax or other governmental charge that may be imposed in
connection therewith.

                                    ARTICLE 2

                            Miscellaneous Provisions

           SECTION 201. Recitals by Company. The recitals in this Twenty-Second
Supplemental Indenture are made by the Company only and not by the Trustee, and
all of the provisions contained in the Original Indenture in respect of the
rights, privileges, immunities, powers and duties of the Trustee shall be
applicable in respect of Series V Notes and of this Twenty-Second Supplemental
Indenture as fully and with like effect as if set forth herein in full.

           SECTION 202. Ratification and Incorporation of Original Indenture. As
heretofore supplemented and as supplemented hereby, the Original Indenture is in
all respects ratified and confirmed, and the Original Indenture as heretofore
supplemented and as supplemented by this Twenty-Second Supplemental Indenture
shall be read, taken and construed as one and the same instrument.

           SECTION 203. Executed in Counterparts. This Twenty-Second
Supplemental Indenture may be simultaneously executed in several counterparts,
each of which shall be deemed to be an original, and such counterparts shall
together constitute but one and the same instrument.

<PAGE>

           IN WITNESS WHEREOF, each party hereto has caused this instrument to
be signed in its name and behalf by its duly authorized officers, all as of the
day and year first above written.

ATTEST:                                     GEORGIA POWER COMPANY

By:/s/Wayne Boston                          By: /s/C.B. Harreld
    Wayne Boston                                  C.B. Harreld
  Assistant Secretary                  Executive Vice President, Treasurer,
                                 Chief Financial Officer and Assistant Secretary

ATTEST:                                     JPMORGAN CHASE BANK, as Trustee

By: /s/Nicholas Sberlati                    By: /s/Carol Ng
      Nicholas Sberlati.                         Carol Ng
       Trust Officer                           Vice President

<PAGE>

                                    EXHIBIT A

                              FORM OF SERIES V NOTE

<PAGE>

NO. ___                                                    CUSIP NO. 373334 FY2

                              GEORGIA POWER COMPANY
                           SERIES V 4.10% SENIOR NOTE
                               DUE AUGUST 15, 2009

       Principal Amount:         $__________________

       Regular Record Date:      15th  calendar day prior to Interest  Payment
                                 Date  (whether or not a Business Day)

       Original Issue Date:      August 20, 2004

       Stated Maturity:          August 15, 2009

       Interest Payment Dates:   February 15 and August 15

       Interest Rate:            4.10% per annum

       Authorized Denomination:  $1,000, or any integral multiple thereof

         Georgia Power Company, a Georgia corporation (the "Company", which term
includes any successor corporation under the Indenture referred to on the
reverse hereof), for value received, hereby promises to pay to __________, or
registered assigns, the principal sum of ______________ DOLLARS ($__________) on
the Stated Maturity shown above, and to pay interest thereon from the Original
Issue Date shown above, or from the most recent Interest Payment Date to which
interest has been paid or duly provided for, semiannually in arrears on each
Interest Payment Date as specified above, commencing on February 15, 2005 and on
the Stated Maturity at the rate per annum shown above until the principal hereof
is paid or made available for payment and on any overdue principal and on any
overdue installment of interest. The interest so payable, and punctually paid or
duly provided for, on any Interest Payment Date (other than an Interest Payment
Date that is the Stated Maturity) will, as provided in such Indenture, be paid
to the Person in whose name this Note (the "Note") is registered at the close of
business on the Regular Record Date as specified above next preceding such
Interest Payment Date, provided that any interest payable at Stated Maturity
will be paid to the Person to whom principal is payable. Except as otherwise
provided in the Indenture, any such interest not so punctually paid or duly
provided for will forthwith cease to be payable to the Holder on such Regular
Record Date and may either be paid to the Person in whose name this Note is
registered at the close of business on a Special Record Date for the payment of
such defaulted interest to be fixed by the Trustee, notice whereof shall be
given to Holders of Notes of this series not less than 10 days prior to such
Special Record Date, or be paid at any time in any other lawful manner not
inconsistent with the requirements of any securities exchange, if any, on which
the Notes of this series shall be listed, and upon such notice as may be
required by any such exchange, all as more fully provided in the Indenture.

         Payments of interest on this Note will include interest accrued to but
excluding the respective Interest Payment Dates. Interest payments for this Note
shall be computed and paid on the basis of a 360-day year of twelve 30-day
months. In the event that any date on which interest is payable on this Note is
not a Business Day, then payment of the interest payable on such date will be
made on the next succeeding day that is a Business Day (and without any interest
or other payment in respect of any such delay), with the same force and effect
as if made on the date the payment was originally payable. A "Business Day"
shall mean any day other than a Saturday or a Sunday or a day on which banking
institutions in New York City are authorized or required by law or executive
order to remain closed or a day on which the Corporate Trust Office of the
Trustee is closed for business.

         Payment of the principal of and interest due at the Stated Maturity of
the Series V Notes shall be made upon surrender of the Series V Notes at the
Corporate Trust Office of the Trustee. The principal of and interest on the
Series V Notes shall be paid in such coin or currency of the United States of
America as at the time of payment is legal tender for payment of public and
private debts. Payment of interest (including interest on an Interest Payment
Date) will be made, subject to such surrender where applicable, at the option of
the Company, (i) by check mailed to the address of the Person entitled thereto
as such address shall appear in the Security Register or (ii) by wire transfer
or other electronic transfer at such place and to such account at a banking
institution in the United States as may be designated in writing to the Trustee
at least 16 days prior to the date for payment by the Person entitled thereto.

         REFERENCE IS HEREBY MADE TO THE FURTHER PROVISIONS OF THIS NOTE SET
FORTH ON THE REVERSE HEREOF, WHICH FURTHER PROVISIONS SHALL FOR ALL PURPOSES
HAVE THE SAME EFFECT AS IF SET FORTH AT THIS PLACE.

         Unless the certificate of authentication hereon has been executed by
the Trustee by manual signature, this Note shall not be entitled to any benefit
under the Indenture or be valid or obligatory for any purpose.

<PAGE>

         IN WITNESS WHEREOF, the Company has caused this instrument to be duly
executed under its corporate seal.

Dated:

                                          GEORGIA POWER COMPANY

                                          By:
                                             -----------------------------
                                          Name:
                                          Title:

Attest:

Title:

                  {Seal of GEORGIA POWER COMPANY appears here}

<PAGE>

                          CERTIFICATE OF AUTHENTICATION

         This is one of the Senior Notes referred to in the within-mentioned
Indenture.

                                           JPMORGAN CHASE BANK,
                                           as Trustee

                                           By:
                                              -----------------------------
                                                    Authorized Officer

<PAGE>

                             (Reverse Side of Note)

         This Note is one of a duly authorized issue of Senior Notes of the
Company (the "Notes"), issued and issuable in one or more series under a Senior
Note Indenture, dated as of January 1, 1998, as supplemented (the "Indenture"),
between the Company and JPMorgan Chase Bank (formerly known as The Chase
Manhattan Bank), as Trustee (the "Trustee," which term includes any successor
trustee under the Indenture), to which Indenture and all indentures incidental
thereto reference is hereby made for a statement of the respective rights,
limitation of rights, duties and immunities thereunder of the Company, the
Trustee and the Holders of the Notes issued thereunder and of the terms upon
which said Notes are, and are to be, authenticated and delivered. This Note is
one of the series designated on the face hereof as Series V 4.10% Senior Notes
due August 15, 2009 (the "Series V Notes") which is unlimited in aggregate
principal amount. Capitalized terms used herein for which no definition is
provided herein shall have the meanings set forth in the Indenture.

         The Series V Notes will not have a sinking fund. The Series V Notes
will not be redeemable at the option of the Company prior to the Stated
Maturity.

         If an Event of Default with respect to the Notes of this series shall
occur and be continuing, the principal of the Notes of this series may be
declared due and payable in the manner, with the effect and subject to the
conditions provided in the Indenture.

         The Indenture permits, with certain exceptions as therein provided, the
amendment thereof and the modification of the rights and obligations of the
Company and the rights of the Holders of the Notes of each series to be affected
under the Indenture at any time by the Company and the Trustee with the consent
of the Holders of not less than a majority in principal amount of the Notes at
the time Outstanding of each series to be affected. The Indenture also contains
provisions permitting the Holders of specified percentages in principal amount
of the Notes of each series at the time Outstanding, on behalf of the Holders of
all Notes of such series, to waive compliance by the Company with certain
provisions of the Indenture and certain past defaults under the Indenture and
their consequences. Any such consent or waiver by the Holder of this Note shall
be conclusive and binding upon such Holder and upon all future Holders of this
Note and of any Note issued upon the registration of transfer hereof or in
exchange hereof or in lieu hereof, whether or not notation of such consent or
waiver is made upon this Note.

         No reference herein to the Indenture and no provision of this Note or
of the Indenture shall alter or impair the obligation of the Company, which is
absolute and unconditional, to pay the principal of and interest on this Note at
the times, place and rates, and in the coin or currency, herein prescribed.

         As provided in the Indenture and subject to certain limitations therein
set forth, the transfer of this Note is registrable in the Security Register,
upon surrender of this Note for registration of transfer at the office or agency
of the Company for such purpose, duly endorsed by, or accompanied by a written
instrument of transfer in form satisfactory to the Company and the Security
Registrar and duly executed by, the Holder hereof or his attorney duly
authorized in writing, and thereupon one or more new Notes of this series, of
authorized denominations and of like tenor and for the same aggregate principal
amount, will be issued to the designated transferee or transferees. No service
charge shall be made for any such registration of transfer or exchange, but the
Company may require payment of a sum sufficient to cover any tax or other
governmental charge payable in connection therewith.

         Prior to due presentment of this Note for registration of transfer, the
Company, the Trustee and any agent of the Company or the Trustee may treat the
Person in whose name this Note is registered as the owner hereof for all
purposes, whether or not this Note be overdue, and neither the Company, the
Trustee nor any such agent shall be affected by notice to the contrary.

         The Notes of this series are issuable only in registered form without
coupons in denominations of $1,000 and any integral multiple thereof. As
provided in the Indenture and subject to certain limitations therein set forth,
Notes of this series are exchangeable for a like aggregate principal amount of
Notes of this series of a different authorized denomination, as requested by the
Holder surrendering the same upon surrender of the Note or Notes to be exchanged
at the office or agency of the Company.

         This Note shall be governed by, and construed in accordance with, the
internal laws of the State of New York.

<PAGE>

                                  ABBREVIATIONS

The following abbreviations, when used in the inscription on the face of this
instrument, shall be construed as though they were written out in full according
to applicable laws or regulations:

<PAGE>

TEN COM- as tenants in            UNIF GIFT MIN ACT- _______ Custodian ________
         common                                       (Cust)           (Minor)
TEN ENT- as tenants by the
         entireties                          under Uniform Gifts to
 JT TEN- as joint tenants                           Minors Act
         with right of
         survivorship and                   ________________________
         not as tenants                            (State)
         in common

                    Additional abbreviations may also be used
                          though not on the above list.

         FOR VALUE RECEIVED, the undersigned hereby sell(s) and transfer(s) unto

(please insert Social Security or other identifying number of assignee)

PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE OF
ASSIGNEE

the within Note and all rights thereunder, hereby irrevocably constituting and
appointing

agent to transfer said Note on the books of the Company, with full power of
substitution in the premises.

Dated:
       --------------------          -----------------------------------------

                                            NOTICE: The signature to this
                                            assignment must correspond with the
                                            name as written upon the face of the
                                            within instrument in every
                                            particular without alteration or
                                            enlargement, or any change whatever.

<PAGE>

                                    EXHIBIT B

                          CERTIFICATE OF AUTHENTICATION

         This is one of the Senior Notes referred to in the within-mentioned
Indenture.

                                                     JPMORGAN CHASE BANK,
                                                     as Trustee

                                                     By:
                                                        -----------------------
                                                           Authorized Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]